var title_f27_16_27904="Grade V traumatic laceration of the spleen";
var content_f27_16_27904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade V traumatic laceration of the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The spleen is fragmented into five discreet pieces on this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Wesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27904=[""].join("\n");
var outline_f27_16_27904=null;
var title_f27_16_27905="Urticarial drug eruption";
var content_f27_16_27905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticarial drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27905=[""].join("\n");
var outline_f27_16_27905=null;
var title_f27_16_27906="Engaged vertex";
var content_f27_16_27906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Engagement of the fetal head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27906=[""].join("\n");
var outline_f27_16_27906=null;
var title_f27_16_27907="Mepivacaine (dental): Drug information";
var content_f27_16_27907=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mepivacaine (dental): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/16/42243?source=see_link\">",
"    see \"Mepivacaine (dental): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg; Dental;",
"     </li>",
"     <li>",
"      Scandonest&reg; 3% Plain",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Polocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia, single site in upper or lower jaw:",
"     </b>",
"     Infiltration: 54 mg (1.8 mL) as a 3% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infiltration and nerve block of entire oral cavity:",
"     </b>",
"     270 mg (9 mL) as a 3% solution; up to a maximum of 6.6 mg/kg of body weight but not to exceed 300 mg per appointment. Manufacturer's maximum recommended dose is not more than 400 mg to normal healthy adults. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required, and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and children doses of mepivacaine dental anesthetic cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 138-9.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthetic: Infiltration and nerve block:",
"     </b>",
"     Children &lt;10 years: Up to 5-6 mg/kg of body weight; maximum pediatric dosage must be carefully calculated on the basis of patient's weight but must not exceed 270 mg (9 mL) of the 3% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &gt;10 years; Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and children doses of mepivacaine dental anesthetic cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 138-9.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 3% (1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbocaine&reg;: 3% (1.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polocaine&reg; Dental: 3% (1.7 mL, 1.8 mL  [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scandonest&reg; 3% Plain: 3% (1.7 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mepivacaine may be confused with bupivacaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of local anesthetic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Myocardial effects include a decrease in contraction force as well as a decrease in electrical excitability and myocardial conduction rate resulting in bradycardia and reduction in cardiac output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: High blood levels result in anxiety, restlessness, disorientation, confusion, dizziness, and seizure. This is followed by depression of CNS resulting in somnolence, unconsciousness and possible respiratory arrest. In some cases, symptoms of CNS stimulation may be absent and the primary CNS effects are somnolence and unconsciousness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersensitivity reactions: May manifest as dermatologic reactions and edema at injection site. Asthmatic syndromes have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psychogenic reactions: It is common to misinterpret psychogenic responses to local anesthetic injection as an allergic reaction. Intraoral injection is perceived by many patients as a stressful procedure in dentistry. Common symptoms to this stress are diaphoresis, palpitation, hyperventilation, generalized pallor and a fainting feeling.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to local anesthetics of the amide type or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14079755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F192990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual infiltration doses of mepivacaine dental anesthetic given to nursing mothers has not been shown to affect the health of the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Polocaine (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Upper jaw: 30-120 seconds; Lower jaw: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Upper jaw: 20 minutes; Lower jaw: 40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: 1.9 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ayoub ST and Coleman AE, &ldquo;A Review of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1992, 40(4):285-7, 289-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27907/abstract-text/1397990/pubmed\" id=\"1397990\" target=\"_blank\">",
"        1397990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27907/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27907/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Recent Research on Mechanisms of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1995, 43(4):316-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27907/abstract-text/8940589/pubmed\" id=\"8940589\" target=\"_blank\">",
"        8940589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10139 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27907=[""].join("\n");
var outline_f27_16_27907=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192996\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192997\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193004\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192998\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193000\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192999\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192985\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192974\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162766\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193008\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193002\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192988\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192978\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192982\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192983\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079754\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079755\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192990\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192991\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192977\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192987\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/16/42243?source=related_link\">",
"      Mepivacaine (dental): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27908="Onchocerciasis distribution in the Americas";
var content_f27_16_27908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Geographic distribution of onchocerciasis in the Americas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 360px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the Onchocerciasis Elimination Program for the Americas (OEPA) and World Health Organization. For more information, visit",
"     <a href=\"file://www.oepa.net\" target=\"_blank\">",
"      www.oepa.net",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27908=[""].join("\n");
var outline_f27_16_27908=null;
var title_f27_16_27909="Drug removal during continuous renal replacement therapy";
var content_f27_16_27909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug removal during continuous renal replacement therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27909/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/16/27909/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different forms of continuous renal replacement therapy are generally reserved for critically ill patients in whom errors in drug dosing may be particularly deleterious [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, knowledge of factors that determine drug removal in this setting is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This discussion is limited to the removal of drugs by CRRTs. Drug elimination is the sum of regional clearances including metabolism as well as the removal by an extracorporeal therapy as are most CRRTs (exception is peritoneal dialysis). In the settings where CRRTs may be applied, the metabolic clearances of drugs may be different from the metabolism of that drug in the normal circumstance. That concept is not discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMOFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemofiltration refers to the removal of an ultrafiltrate of plasma in which there is no solute loss by diffusion, since the plasma flowing through the filter is not exposed to dialysate flowing on the other side of the membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .) Solute removal during hemofiltration occurs by convection (or solvent drag). The frictional forces between water and solutes results in the movement of small and middle molecular weight solutes (less than 5000 daltons) in the same direction as plasma water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sieving coefficient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of the removal of drugs or any other solute is related to the sieving coefficient. The sieving coefficient (SC) is the mathematical expression of the ability of a solute to convectively cross a membrane. It is determined from the ratio of the solute concentration in the ultrafiltrate to the solute concentration in the plasma. Since the arterial and venous concentrations may be different because of solute removal, it is more accurate to estimate the SC during hemofiltration from the average of the arterial (A) and venous (V) concentrations:",
"   </p>",
"   <p>",
"    &nbsp;SC &nbsp; = &nbsp; [UF] &nbsp;&divide; &nbsp;([A] &nbsp;+ &nbsp;[V] &nbsp;&divide; &nbsp;2)",
"   </p>",
"   <p>",
"    where UF represents the solute concentration in the ultrafiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/3\">",
"     3",
"    </a>",
"    ]. An SC of 1 means that the solute freely crosses the membrane and is removed in the same concentration as in the plasma, while an SC of 0 means that there is no solute removal due either to large molecular size or to extensive protein binding (see below).",
"   </p>",
"   <p>",
"    With continuous hemofiltration, there is no solute loss by diffusion. As a result, the venous concentration will be equal to arterial if the SC is 1 and slightly greater than arterial if the SC is less than 1 because more water than solute will be removed. This difference is not clinically significant for most drugs and it can be assumed that the arterial and venous concentrations are the same. There is therefore no need for a venous sample and the above equation can be simplified to [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;SC &nbsp; = &nbsp; [UF] &nbsp;&divide; &nbsp;[A]",
"   </p>",
"   <p>",
"    Plasma water makes up about 93 percent of the plasma, so that the difference between the measured plasma and physiologically important plasma water concentrations can be ignored clinically.",
"   </p>",
"   <p>",
"    The SC is constant during continuous arteriovenous or venovenous hemofiltration (CAVH or CVVH). As a result:",
"   </p>",
"   <p>",
"    &nbsp;Rate of solute clearance &nbsp; = &nbsp; SC &nbsp;x &nbsp;ultrafiltration rate",
"   </p>",
"   <p>",
"    Increasing the rate of ultrafiltration will therefore enhance solute clearance as well.",
"   </p>",
"   <p>",
"    The SC for several drugs is different through polyacrylonitrile or polyamide membranes than through polysulfone membranes because of drug-membrane interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/5\">",
"     5",
"    </a>",
"    ]. Drug charge, for example, can affect both convective and diffusive transport depending on the nature of the drug-membrane-charge interaction. This charge effect can alter the removal of such drugs as aminoglycosides, cephalosporins, and penicillins.",
"   </p>",
"   <p>",
"    Certain drugs can also bind to dialysis membranes, especially the aminoglycoside antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. A Biospal AN69 membrane filter, for example, binds 10 to 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of molecular size and protein binding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular size of most drugs is less than the maximum size freely removed by convection during hemofiltration. As a result, size is not an important determinant of drug removal with this procedure. It is, however, important with diffusive loss during hemodialysis, since larger molecules diffuse through the membrane more slowly (see below).",
"   </p>",
"   <p>",
"    The major determinant of drug removal by hemofiltration is binding to nonultrafilterable plasma proteins. Only",
"    <strong>",
"     unbound",
"    </strong>",
"    drug can be removed. Multiple factors influence the degree of protein binding of a drug including pH, molar concentration of drug and protein, bilirubin, uremic inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , free fatty acids, and the presence of displacing drugs. The importance of these factors varies from drug to drug. As an example, free fatty acids displace cefamandole but enhance the binding of other cephalosporins such as cephalothin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/9\">",
"     9",
"    </a>",
"    ]. Free fatty acids increase the SC of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SC data from our experience and the literature are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef73902 \" href=\"UTD.htm?9/10/9390\">",
"     table 1",
"    </a>",
"    ). Also shown for comparison is the unbound fraction which, for most drugs, correlates closely with the SC. An even tighter correlation occurs when the SC is defined more accurately as:",
"   </p>",
"   <p>",
"    &nbsp;SC &nbsp; = &nbsp; AUC-UF &nbsp;&divide; &nbsp;AUC-P",
"   </p>",
"   <p>",
"    where AUC-UF and AUC-P represent the areas under the time-drug concentration curves for ultrafiltrate and plasma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Total drug removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the total amount of drug removed during hemofiltration permits the physician to calculate the dose supplement that is needed. There are two formulas that can be used if drug levels can be measured. The first formula uses the drug concentration in the ultrafiltrate:",
"   </p>",
"   <p>",
"    &nbsp;Amount of drug removed, mg",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;= &nbsp; Ultrafiltrate concentration",
"    <span class=\"nowrap\">",
"     (mg/L)",
"    </span>",
"    &nbsp;x &nbsp;ultrafiltration rate",
"    <span class=\"nowrap\">",
"     (L/min)",
"    </span>",
"    &nbsp;x &nbsp;time of",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;procedure (min)",
"   </p>",
"   <p>",
"    An alternative to measuring ultrafiltrate levels is to extrapolate the ultrafiltrate concentration from the arterial level (if available for the particular drug).",
"   </p>",
"   <p>",
"    &nbsp;Ultrafiltrate concentration &nbsp; = &nbsp; Plasma concentration",
"    <span class=\"nowrap\">",
"     (mg/L)",
"    </span>",
"    &nbsp;x &nbsp;unbound fraction",
"   </p>",
"   <p>",
"    The unbound fraction for some commonly used drugs can be determined from the table (",
"    <a class=\"graphic graphic_table graphicRef73902 \" href=\"UTD.htm?9/10/9390\">",
"     table 1",
"    </a>",
"    ) or by searching for pharmacokinetic information on the desired drug elsewhere in UpToDate.",
"   </p>",
"   <p>",
"    &nbsp;Unbound fraction &nbsp; = &nbsp; (100 &nbsp;- &nbsp;percent bound) &nbsp;&divide; &nbsp;100",
"   </p>",
"   <p>",
"    The available protein binding data were usually obtained from studies in healthy people [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/12\">",
"     12",
"    </a>",
"    ]. Slight discrepancies may arise when applying these data to critically ill patients.",
"   </p>",
"   <p>",
"    These values can be substituted for the ultrafiltrate concentration in the above formula.",
"   </p>",
"   <p>",
"    &nbsp;Amount of drug removed, mg",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;= &nbsp; Plasma concentration",
"    <span class=\"nowrap\">",
"     (mg/L)",
"    </span>",
"    &nbsp;x &nbsp;unbound fraction &nbsp;x &nbsp;ultrafiltration rate",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     (L/min)",
"    </span>",
"    &nbsp;x &nbsp;time of procedure (min)",
"   </p>",
"   <p>",
"    The plasma sample should represent a",
"    <strong>",
"     steady state",
"    </strong>",
"    level. The ideal time to obtain this sample is halfway between maintenance doses after at least three half-lives. Half-life data can be obtained by searching for pharmacokinetic information on the desired drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above formulas are applicable only for the small number of drugs for which plasma levels are easily obtainable. For most drugs, it is necessary to estimate the average steady state plasma concentration from the dosing regimen and rate of clearance:",
"   </p>",
"   <p>",
"    &nbsp;Average drug concentration &nbsp; = &nbsp; Dosing rate",
"    <span class=\"nowrap\">",
"     (mg/min)",
"    </span>",
"    &nbsp;&divide; &nbsp;Clearance",
"    <span class=\"nowrap\">",
"     (mL/min)",
"    </span>",
"   </p>",
"   <p>",
"    The dosing rate is the infusion rate for a drug given by continuous intravenous infusion or the dose divided by the dosing interval if given intermittently. Clearance is the value for clearance for the patient's level of renal function (obtained by searching for pharmacokinetic information on the specific drug) multiplied by the patient's weight in kilograms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug removal during continuous arteriovenous or venovenous hemodialysis (CAVHD or CVVHD) occurs primarily by diffusion into the drug-free dialysate; convection is less important, since the ultrafiltration rate is held at a much lower level than with hemofiltration alone.",
"   </p>",
"   <p>",
"    The removal of a solute by dialysis is dependent on the diffusivity of that solute across that particular membrane. The clearance by dialysis can be measured easily and is the product of the ratio of the dialysate concentration to the plasma concentration",
"    <span class=\"nowrap\">",
"     (D/P)",
"    </span>",
"    times the dialysate effluent flow rate. This assumes no clearance from the plasma by adsorption to the dialysis membrane. The",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratio is sometimes called the saturation ratio because it is a measure of the degree of saturation of the dialysate with the solute in question. A",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    of unity means the dialysate is fully saturated with the solute and the clearance would simply be the effluent flow rate.",
"   </p>",
"   <p>",
"    There are two limiting factors to drug removal by diffusion: protein-binding and molecular size [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Membrane permeability is also an important determinant of drug removal. A drug with a molecular weight of 500 daltons will be partially dialyzed through conventional membranes, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    at 1400 daltons is appreciably dialyzed through more open membranes like those employed with continuous hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/14\">",
"     14",
"    </a>",
"    ]. Even within membranes of a given class, however, there may be appreciable differences in drug clearance due to differences in pore size and perhaps charge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diffusive mass transfer coefficient (K) of a drug through the \"open\" membranes used with continuous hemodialysis is dependent upon molecular weight according to the formula [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;K-drug",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    K-creatinine &nbsp; = &nbsp; (mol wt &nbsp;&divide; &nbsp;113) to the -0.42 power",
"   </p>",
"   <p>",
"    As molecular weight increases, drug diffusion progressively decreases and dialyzer clearance becomes less dependent on blood and dialysate flow rates. In this setting, drug removal occurs primarily by convection during ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solute losses during combined convection and diffusion are less than the sum of each transport process individually [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/18\">",
"     18",
"    </a>",
"    ]. This has been shown nicely in two separate studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    removal under two operating conditions differing mainly by rate of ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The presence of convectively derived solute in the dialysate decreases the concentration gradient for further diffusion. This effect can be overcome by increasing the dialysate flow rate and is less important at lower ultrafiltrate rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the desired plasma drug concentration is known, both loading and maintenance doses can be determined by the following strategy. The presently observed level is subtracted from the level one wishes to achieve. This difference (in",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    times the volume of distribution (in",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    times the body weight (in kg) represents the amount of drug required to boost the present level to the desired level. (Search elsewhere in UpToDate on pharmacokinetics of the individual drug to determine the volume of distribution.)",
"   </p>",
"   <p>",
"    For loading doses, the present level is zero and the difference level is the desired level. For maintenance doses, the trough level is the present level. This method can also be used to replace drug removed during continuous renal replacement therapy when the amount of drug removed has not been directly calculated as noted above.",
"   </p>",
"   <p>",
"    As the dose of dialysis (or any renal replacement therapy) increases, more drug may be removed, which also depends upon the drug's unique pharmacokinetics. This will therefore impact drug dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/21\">",
"     21",
"    </a>",
"    ]. Pharmacokinetic principles tend to be consistent and knowledge of them is crucial with application of the rapidly evolving renal replacement therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27909/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The different forms of continuous renal replacement therapy are generally reserved for critically ill patients. In this setting, errors in drug dosing may be particularly deleterious. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemofiltration refers to the removal of an ultrafiltrate of plasma in which there is no solute loss by diffusion. With hemofiltration, the efficiency of the removal of drugs or any other solute is related to the sieving coefficient. The sieving coefficient (SC) is the mathematical expression of the ability of a solute to convectively cross a membrane. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sieving coefficient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The molecular size of most drugs is less than the maximum size freely removed by convection during hemofiltration. As a result, size is not an important determinant of drug removal with this procedure, but it is important with hemodialysis. The major determinant of drug removal by hemofiltration is binding to nonultrafilterable plasma proteins. Only",
"      <strong>",
"       unbound",
"      </strong>",
"      drug can be removed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of molecular size and protein binding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calculation of the total amount of drug removed during hemofiltration permits the physician to calculate the dose supplement that is needed. There are two formulas that can be used if drug levels can be measured. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Total drug removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug removal during continuous arteriovenous or venovenous hemodialysis (CAVHD or CVVHD) occurs primarily by diffusion into the drug-free dialysate; convection is less important, since the ultrafiltration rate is held at a much lower level than with hemofiltration alone. The removal of a solute by dialysis is dependent on the diffusivity of that solute across that particular membrane. There are two limiting factors to drug removal by diffusion: protein-binding and molecular size. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General issues surrounding drug dosing in continuous renal replacement therapies are discussed above. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Drug dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/1\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/2\">",
"      Joy MS, Matzke GR, Armstrong DK, et al. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998; 32:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/3\">",
"      Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 1975; 85:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/4\">",
"      Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985; 8:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/5\">",
"      Kronfol NO, Lau AH, Colon-Rivera J, Libertin CL. Effect of CAVH membrane types on drug-sieving coefficients and clearances. ASAIO Trans 1986; 32:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/6\">",
"      Rumpf KW, Rieger J, Ansorg R, et al. Binding of antibiotics by dialysis membranes and its clinical relevance. Proc Eur Dial Transplant Assoc 1977; 14:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/7\">",
"      Kraft D, Lode H. Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 1979; 57:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/8\">",
"      Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans 1987; 33:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/9\">",
"      Suh B, Craig WA, England AC, Elliott RL. Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis 1981; 143:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/10\">",
"      Golper TA, Saad AM. Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Kidney Int 1986; 30:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/11\">",
"      Kroh U, Hofmann W, Dehne M, et al. [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study]. Anaesthesist 1989; 38:225.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: Dosing guidelines for adults and children, 5th ed, American College of Physicians, Philadelphia 2007.",
"    </li>",
"    <li>",
"     Henderson, LW. Hemodialysis: Rationale and physical principles. In: The Kidney, 1st ed, Brenner, BM, Rector, FC (Eds), Saunders, Philadelphia 1976. p.1643-1671.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/14\">",
"      De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989; 4:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/15\">",
"      Agarwal R, Cronin RE. Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis 1994; 23:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/16\">",
"      Vincent HH, Vos MC, Ak&ccedil;ahuseyin E, et al. Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif 1993; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/17\">",
"      Golper TA, Cigarran-Guldris S, Jenkins RD, Brier ME. The role of convection during simulated continuous arteriovenous hemodialysis. Contrib Nephrol 1991; 93:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/18\">",
"      Sprenger KG, Stephan H, Kratz W, et al. Optimising of hemodiafiltration with modern membranes? Contrib Nephrol 1985; 46:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/19\">",
"      Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/20\">",
"      Tegeder I, Neumann F, Bremer F, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/21\">",
"      Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/22\">",
"      Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27909/abstract/23\">",
"      Matzke G, Aronoff GR, Atkinson A, et al. Drug dosing considerations in patients with acute and chronic kidney disease. Kidney Int 2011.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1932 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27909=[""].join("\n");
var outline_f27_16_27909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMOFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sieving coefficient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of molecular size and protein binding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Total drug removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/10/9390\" title=\"table 1\">",
"      Sieving Coefficients for Drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27910="Aluminum hydroxide: Drug information";
var content_f27_16_27910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/29/12756?source=see_link\">",
"    see \"Aluminum hydroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"    see \"Aluminum hydroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ALternaGel&reg; [OTC];",
"     </li>",
"     <li>",
"      Dermagran&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amphojel&reg;;",
"     </li>",
"     <li>",
"      Basaljel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid;",
"     </li>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Protectant, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperphosphatemia:",
"     </b>",
"     Oral: Initial: 300-600 mg 3 times/day with meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperacidity:",
"     </b>",
"     Oral: 600-1200 mg between meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Skin protectant:",
"     </b>",
"     Topical: Apply to affected area as needed; reapply at least every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F132488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"      see \"Aluminum hydroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hyperphosphatemia:",
"     </b>",
"     Oral: 50-150 mg/kg/24 hours in divided doses every 4-6 hours, titrate dosage to maintain serum phosphorus within normal range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Skin protectant:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum may accumulate in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermagran&reg;: 0.275% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 320 mg/5 mL (30 mL [DSC], 360 mL, 473 mL, 480 mL); 600 mg/5 mL (355 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALternaGel&reg;: 600 mg/5 mL (360 mL) [sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: Dose should be followed with water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Topical: Apply as needed to affected area; reapply at least every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperacidity; hyperphosphatemia; temporary protection of minor cuts, scrapes, and burns",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, discoloration of feces (white speckles), fecal impaction, nausea, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia, hypophosphatemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aluminum salts or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: Hypophosphatemia may occur with prolonged administration or large doses; aluminum intoxication and osteomalacia may occur in patients with uremia. Use with caution in patients with HF, renal failure, edema, cirrhosis, and low sodium diets, and patients who have recently suffered gastrointestinal hemorrhage; uremic patients not receiving dialysis may develop osteomalacia and osteoporosis due to phosphate depletion. When used as an antacid in ulcer treatment, consider buffer capacity (mEq/mL) to calculate dose. Elderly may be predisposed to constipation and fecal impaction. Careful evaluation of possible drug interactions must be done.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Not for application over deep wounds, puncture wounds, infected areas, or lacerations. When used for self medication (OTC use), consult with healthcare provider if needed for &gt;7 days or for use in children &lt;6 months of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13826370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Aluminum hydroxide may cause constipation with inadequate hydration. Management: Maintain proper hydration unless instructed otherwise by physician. Take preferably 1-3 hours after meals (when used as an antacid). When used to decrease phosphorus, take within 20 minutes of a meal.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum-containing antacids are considered low risk during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1-3 hours after meals when used as an antacid. When used to decrease phosphorus, should be taken within 20 minutes of a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Aluminum Hydroxide Gel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320 mg/5 mL (473 mL): $5.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F132460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor calcium and phosphorus levels periodically when patient is on chronic therapy.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldrox (BE);",
"     </li>",
"     <li>",
"      Algeldraat (NL);",
"     </li>",
"     <li>",
"      Alu-Cap (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Alu-Tab (AU, HK, SG);",
"     </li>",
"     <li>",
"      Alucol (IT);",
"     </li>",
"     <li>",
"      Aludrox (DE);",
"     </li>",
"     <li>",
"      Alugel (DE, TW);",
"     </li>",
"     <li>",
"      Alumigel (JP);",
"     </li>",
"     <li>",
"      Alutab (MY);",
"     </li>",
"     <li>",
"      Alzinox (PH);",
"     </li>",
"     <li>",
"      Amphogel (KP);",
"     </li>",
"     <li>",
"      Amphojel (ZA);",
"     </li>",
"     <li>",
"      Gastracol (CH);",
"     </li>",
"     <li>",
"      Pepsamar (BF, BJ, BR, CI, CN, CO, ES, ET, GH, GM, GN, GR, KE, LR, MA, ML, MR, MU, MW, NE, NG, PE, PT, SC, SD, SL, SN, TN, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Rocgel (FR);",
"     </li>",
"     <li>",
"      Sukit (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neutralizes hydrochloride in stomach to form Al (Cl)",
"     <sub>",
"      3",
"     </sub>",
"     salt + H",
"     <sub>",
"      2",
"     </sub>",
"     O",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bohannon AD and Lyles KW, &ldquo;Drug-Induced Bone Disease,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1994, 10(4):611-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/7850693/pubmed\" id=\"7850693\" target=\"_blank\">",
"        7850693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cumming RG and Klineberg RJ, &ldquo;Aluminum in Antacids and Cooking Pots and the Risk of Hip Fractures in Elderly People,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1994, 23:468-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/9231940/pubmed\" id=\"9231940\" target=\"_blank\">",
"        9231940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S and Ahlawat SK, &ldquo;Aluminum Phosphide Poisoning - A Review,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(1):19-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/7837309/pubmed\" id=\"7837309\" target=\"_blank\">",
"        7837309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maher ER, Brown EA, Curtis JR, et al, &ldquo;Accumulation of Aluminum in Chronic Renal Failure Due to Administration of Albumin Replacement Solutions,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1986, 292(6516):306.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monteagudo FS, Cassidy MJ, and Folb PI, &ldquo;Recent Developments in Aluminum Toxicity,&rdquo;",
"      <i>",
"       Med Toxicol Adverse Drug Exp",
"      </i>",
"      , 1989, 4(1):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/2651849/pubmed\" id=\"2651849\" target=\"_blank\">",
"        2651849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robertson JA, Salusky IB, Goodman WG, et al, &ldquo;Sucralfate, Intestinal Aluminum Absorption, and Aluminum Toxicity in a Patient on Dialysis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1989, 111(2):179-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27910/abstract-text/2742249/pubmed\" id=\"2742249\" target=\"_blank\">",
"        2742249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Department of Health and Human Services, &ldquo;Toxicological Profile for Aluminum TP-91/01,&rdquo; Agency for Toxic Substances and Diseases Registry, July 1992.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8499 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27910=[""].join("\n");
var outline_f27_16_27910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132475\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132476\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132492\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132478\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132488\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132479\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132480\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132462\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132447\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132465\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132464\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132490\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132467\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132451\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298721\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132456\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13826370\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132469\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132470\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322975\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132460\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132471\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132450\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/29/12756?source=related_link\">",
"      Aluminum hydroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=related_link\">",
"      Aluminum hydroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27911="Primary biliary cirrhosis II";
var content_f27_16_27911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of liver biopsy in primary biliary cirrhosis in the same patient showing a marked mononuclear cell infiltrate surrounding and destroying a bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sanjiv Chopra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27911=[""].join("\n");
var outline_f27_16_27911=null;
var title_f27_16_27912="Epidemiology and etiology of epistaxis in children";
var content_f27_16_27912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and etiology of epistaxis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Anna H Messner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27912/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/16/27912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis is common in children. Childhood nosebleeds are rarely severe and seldom require hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonetheless, frequent minor nosebleeds can be both bothersome and alarming for parents and children.",
"   </p>",
"   <p>",
"    The epidemiology and etiology of epistaxis in children will be reviewed here. The evaluation and management of epistaxis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link\">",
"     \"Management of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few recent data on the prevalence of nosebleeds in children. One 1979 study found that 30 percent of children younger than five years and 56 percent of children aged 6 to 10 years had had at least one nosebleed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of epistaxis declines in adulthood, but approximately one-half of all adults with epistaxis had nosebleeds during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/3\">",
"     3",
"    </a>",
"    ]. Epistaxis is rare in children younger than two years (approximately 1 per 10,000) and should prompt consideration of trauma (intentional or unintentional) or serious illness (eg, thrombocytopenia) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Some pediatric health care providers believe that when a young baby bleeds from the nose, or is reported to have had a nosebleed, that child abuse must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epistaxis that occurs in children younger than 10 years usually is mild and originates in the anterior nose, whereas epistaxis that occurs in individuals older than 50 years is more likely to be severe and to originate posteriorly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the National Hospital Ambulatory Medical Care Survey indicate that epistaxis accounted for &lt;1 percent of all emergency department visits between 1992 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/10\">",
"     10",
"    </a>",
"    ]. Overall, there were approximately two emergency department visits for epistaxis per 1000 population annually. The age-related frequency was bimodal with one peak in individuals younger than 10 years (4 per 1000 population) and a second peak in those 70 to 79 years.",
"   </p>",
"   <p>",
"    An increased incidence of epistaxis occurs during cold weather and when ambient humidity is low, both of which make the nasal septal mucosa dry and friable, and predisposed to bleeding, even with minor trauma as may occur with nose rubbing, blowing, or sneezing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Increased atmospheric pollutant concentrations (in the form of airborne particulate matter and atmospheric ozone) also can irritate the nasal respiratory epithelium, leading to increased incidence of epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nose is a highly vascular structure with a large surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13\">",
"     13",
"    </a>",
"    ]. These qualities enable the nose to filter, humidify, and warm inhaled air [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], but also predispose it to bleeding.",
"   </p>",
"   <p>",
"    One of the most vascular areas of the nose is Kiesselbach's plexus in the anterior nasal septum (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Kiesselbach's plexus is formed by the anastomosis of terminal vessels from the internal and external carotid arteries. Specifically, the septal branch of the anterior ethmoidal artery; the lateral nasal branch of the sphenopalatine artery; and the septal branch of the superior labial branch of the facial artery all end in Kiesselbach's plexus (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ). In addition, the branches of the sphenopalatine artery supply the posterolateral wall and posterior choana; these vessels are the most likely source of posterior nosebleeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal mucosa is closely applied to the nasal septum and provides little anatomic support or protection for the underlying blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"     14",
"    </a>",
"    ]. Any factors that cause congestion of the nasal vessels, or drying or irritation of the nasal mucosa, increase the likelihood of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosebleeds in children have a variety of etiologies, ranging from self-limited mucosal irritation to life-threatening neoplasms (",
"    <a class=\"graphic graphic_table graphicRef67540 \" href=\"UTD.htm?17/47/18172\">",
"     table 1",
"    </a>",
"    ). Common causes of nosebleeds in children include mucosal dryness, trauma, foreign body, and rhinitis (allergic, infectious, or related to mucosal irritation). Less common, but important causes of nosebleeds to remember include bleeding disorders and other systemic diseases, tumors, and post-traumatic pseudoaneurysm of the internal carotid artery.",
"   </p>",
"   <p>",
"    Several classification schemes have been used to categorize nosebleeds. One categorizes the bleeding according to site: anterior versus posterior. Anterior nosebleeds, usually arising from Kiesselbach's plexus (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ), are most common (accounting for approximately 90 percent of nosebleeds in children) and are almost always self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Anterior nosebleeds usually result from mucosal dryness, trauma, or irritation, although many cases are idiopathic. Posterior nose bleeds are unusual in children and usually due to significant nasal trauma. Posterior bleeds usually arise from the posterolateral branches of the sphenopalatine artery (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another classification scheme considers whether bleeding arises from local or systemic conditions (",
"    <a class=\"graphic graphic_table graphicRef67540 \" href=\"UTD.htm?17/47/18172\">",
"     table 1",
"    </a>",
"    ). Local causes of bleeding, which predominate in children, include trauma, mucosal irritation or drying, anatomic abnormalities, and nasopharyngeal masses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Systemic causes of epistaxis include bleeding disorders (eg, inherited or acquired factor deficiencies, platelet disorders, or disorders of vessels), medications, neoplasms, inflammatory disorders, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Children with systemic predisposing factors rarely present with epistaxis as the only manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Local causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nose picking &ndash; In children, trauma to the septum due to nose picking is common, and parents and patients should be routinely queried about the frequency of nose picking when evaluating a child for nosebleeds. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"       \"Evaluation of epistaxis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Facial and head trauma &ndash; Blunt facial trauma may result in significant bleeding that is usually anterior in origin, and often related to septal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,17,19\">",
"       13,17,19",
"      </a>",
"      ]. The anterior ethmoidal artery, which enters the nasal cavity through the fragile lamina papyracea of the ethmoid bone, can be lacerated by bone fragments in mid-face trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/19\">",
"       19",
"      </a>",
"      ]. Massive epistaxis after head injury is suggestive of internal carotid pseudoaneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/20-22\">",
"       20-22",
"      </a>",
"      ], but this entity also may present initially with mild epistaxis or with recurrent epistaxis that does not respond to conservative management [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. Child abuse may also be a cause of epistaxis, particularly in the child younger than one year of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Foreign body &ndash; When epistaxis is unilateral and accompanied by foul-smelling nasal drainage, a foreign body must be presumed present until proven otherwise [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/19,26\">",
"       19,26",
"      </a>",
"      ]. The foreign body can cause mucosal irritation, laceration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/26\">",
"       26",
"      </a>",
"      ]. If the foreign body has been in the nose for only a short time (minutes to hours), its attempted removal by the patient or parent may be the cause of the nosebleed [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/27\">",
"       27",
"      </a>",
"      ]. If the foreign body has been in place for several days, the fetid nasal drainage will commonly be blood-stained. Nasal foreign bodies most frequently are found in the floor of the nose just below the inferior turbinate [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/28\">",
"       28",
"      </a>",
"      ]. Common nasal foreign bodies include beads, rubber erasers, paper wads, pebbles, marbles, beans, peas, nuts, sponges, and chalk. Button batteries require immediate removal to prevent septal perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative &ndash; Postoperative epistaxis may occur after adenoidectomy, sinus surgery, septal surgery, rhinoplasty,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      turbinectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,17\">",
"       13,17",
"      </a>",
"      ]. Postoperative epistaxis can occur up to two weeks post-operatively and in most cases will resolve spontaneously. Otolaryngology intervention occasionally is needed to control the bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link\">",
"       \"Management of epistaxis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nasotracheal intubation and nasogastric tube placement &ndash; Nasotracheal intubation and nasogastric tube placement may tear the nasal mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13\">",
"       13",
"      </a>",
"      ]. This is primarily a concern in children with coagulopathies who are being cared for in the intensive care unit.",
"     </li>",
"     <li>",
"      Barotrauma &ndash; Barotrauma, as occurs with scuba diving, may contribute to epistaxis in patients with upper respiratory infection or allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H8#H8\">",
"       \"Complications of scuba diving\", section on 'Sinus barotrauma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mucosal irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritation of the nasal mucosa may be caused by a number of factors, including changes in humidity, allergies, viral or bacterial upper respiratory infections, chronic rhinitis with frequent nose blowing and increased vascularity and friability of the nasal mucosa, chronic usage of nasal sprays or drying agents, intentional or unintentional exposure to irritant inhalants or substances of abuse (eg, tobacco smoke, cocaine, heroin, volatile inhalants) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,14,26,30\">",
"     13,14,26,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic rhinitis &ndash; Allergic rhinitis is another cause of nosebleeds in children; sneezing, nose rubbing, and treatment with nasal corticosteroids may exacerbate or precipitate epistaxis in these children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/18,30\">",
"       18,30",
"      </a>",
"      ]. One study found that children with allergic rhinitis (defined by nasal symptoms and a positive skin test to common inhalant allergens), had more nosebleeds than their peers without allergic rhinitis (20 percent compared to: 10 percent in those with only nasal symptoms; 3 percent in those with only a positive skin test; and 2 percent in those with neither nasal symptoms nor a positive skin test) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection &ndash; Viral and bacterial upper respiratory infections, including sinusitis, and systemic illnesses that are accompanied by nasal congestion result in inflammation of the nasal mucosa, with increased likelihood of bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,17\">",
"       14,17",
"      </a>",
"      ]. Nasal colonization with Staphylococcus aureus appears to play a prominent role in leading to the mucosal irritation associated with childhood epistaxis. In one study, 24 of 42 (57 percent) children with epistaxis had S. aureus cultured from their anterior nasal cavities, compared to 6 of 19 (24 percent) children with no history of nasal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Local skin infections (eg, staphylococcal furuncles), also may cause epistaxis. Nasal tuberculosis is a rare, chronic, granulomatous infection that can cause nasal obstruction and epistaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/33\">",
"       33",
"      </a>",
"      ]. Dengue hemorrhagic fever can also cause nasal bleeding in affected children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Other infections that may cause blood-tinged nasal discharge (rather than frank epistaxis) include nasal Streptococcus pyogenes infection, congenital syphilis, and nasal diphtheria (rare) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms of the nasal cavity usually cause unilateral symptoms such as intermittent epistaxis, foul discharge, nasal obstruction, or change in smell sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/26\">",
"     26",
"    </a>",
"    ]. Severe bleeding is uncommon, except in patients with vascular tumors such as juvenile nasopharyngeal angiofibroma.",
"   </p>",
"   <p>",
"    Benign localized neoplasms that can cause epistaxis in children include juvenile nasopharyngeal angiofibromas, hemangiomas, and pyogenic granulomas, and inverting papillomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. Malignant neoplasms of the nose, sinuses, or nasopharynx are rare but important causes of epistaxis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/18\">",
"     18",
"    </a>",
"    ]. They include rhabdomyosarcoma and nasopharyngeal carcinoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Juvenile nasopharyngeal angiofibroma &ndash; Juvenile nasopharyngeal angiofibroma is a histologically benign tumor that is markedly vascular and can cause severe epistaxis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76702 \" href=\"UTD.htm?33/3/33842\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/36\">",
"       36",
"      </a>",
"      ]. It occurs primarily in adolescent males [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,14,17,19\">",
"       13,14,17,19",
"      </a>",
"      ]. The lesions arise in the lateral nasopharynx and are hormonally sensitive [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/19\">",
"       19",
"      </a>",
"      ]. Their blood supply is derived from the internal maxillary artery. Although juvenile nasopharyngeal angiofibroma is a benign tumor, it can cause severe problems through local invasion of adjacent structures [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The clinical features of juvenile nasopharyngeal angiofibroma were described in a review of 120 cases from the Mayo Clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/37\">",
"       37",
"      </a>",
"      ]. The mean patient age was 15 years (range 7 to 29 years). The triad of nasal obstruction, epistaxis, and nasal drainage was the most common combination of signs and symptoms; serous otitis media and diminished hearing also may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/19,37,38\">",
"       19,37,38",
"      </a>",
"      ]. The tumors may bulge into the nasal cavity, but often require examination of the nasopharynx to be identified [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,37\">",
"       14,37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The diagnosis is usually confirmed by computed tomography or magnetic resonance imaging with contrast that shows a vascular enhancing nasopharyngeal mass with involvement and widening of the pterygomaxillary fissure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17,37,39\">",
"       17,37,39",
"      </a>",
"      ]. Intranasal biopsy of these lesions should be avoided because of the risk of life-threatening bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyogenic granuloma &ndash; Pyogenic granuloma, also known as granuloma telangiectaticum, is a benign tumor associated with capillary proliferation. Pyogenic granuloma often, but not always, occurs after a history of trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29785?source=see_link\">",
"       \"Pyogenic granuloma (Lobular capillary hemangioma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhabdomyosarcoma &ndash; Rhabdomyosarcoma may present with episodic epistaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17\">",
"       17",
"      </a>",
"      ]. Parameningeal rhabdomyosarcoma can cause nasal, aural, or sinus obstruction with or without mucopurulent or bloody nasal discharge. Other signs and symptoms include middle ear effusion, deep facial pain, and cranioneuropathies, such as sixth nerve palsy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nasopharyngeal carcinoma &ndash; Nasopharyngeal carcinoma in children may present with epistaxis, rhinitis, headache, torticollis, trismus, unilateral cervical lymphadenopathy, retrobulbar or ear pain, hearing loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neck pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,38,41-43\">",
"       14,38,41-43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inverting papillomas &ndash; Inverting (or inverted) papillomas, which grow with an inversion of the epithelium into the connective tissue stroma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/44\">",
"       44",
"      </a>",
"      ], are rare in children. They manifest as unilateral red, polypoid masses attached to the lateral nasal wall, middle turbinate, the septum, or the nasal vestibule [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/45\">",
"       45",
"      </a>",
"      ]. Approximately two percent may undergo malignant transformation, which typically occurs in adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased nasal venous pressure secondary to paroxysmal coughing as occurs in pertussis or cystic fibrosis occasionally may cause nosebleeds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Systemic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic causes of nosebleeds in children include bleeding diathesis, disorders of blood vessels, medications, neoplasms, inflammatory disorders, and hypertension. Epistaxis is rarely the only manifestation of systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14\">",
"     14",
"    </a>",
"    ]. Systemic disease should be considered in children with constitutional signs and symptoms, severe or recurrent nosebleeds, and a family history of bleeding disorder or other heritable systemic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding disorders must be considered in children with recurrent, frequent, spontaneous epistaxis and those with a prolonged, difficult-to-control nosebleed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Bleeding disorders encompass inherited and acquired disorders of coagulation, platelet disorders, and disorders of blood vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study of 178 children referred to a pediatric hematologist for recurrent epistaxis found 59 children (33 percent) had a bleeding disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/47\">",
"     47",
"    </a>",
"    ]. Of these 59 children, von Willebrand disease was found in 33 (56 percent), platelet aggregation disorders in 10, thrombocytopenia in seven, mild factor VIII deficiency in three, Bernard-Soulier syndrome in two, factor VII deficiency in one, factor IX deficiency in one, factor XI deficiency in one, and coagulation inhibitor in one. Of the historic data collected, only a family history of bleeding was found to be predictive of a bleeding disorder. Children with bleeding disorders had a longer median partial thromboplastin time (PTT) of 33.1 versus 30.5 seconds.",
"   </p>",
"   <p>",
"    In another prospective study, 36 children with five or more nosebleeds per year and 35 control children who were admitted for minor elective surgery were evaluated for mild bleeding disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/49\">",
"     49",
"    </a>",
"    ]. Two children with epistaxis were found to have type I von Willebrand disease.",
"   </p>",
"   <p>",
"    People with blood group O have a lower expression of von Willebrand factor (factor IX) and thus a relative bleeding tendency. A retrospective study of Caucasian patients with epistaxis admitted to hospitals in the United Kingdom over a six-year period revealed a higher prevalence of blood group O in patients admitted with epistaxis compared with controls. This study suggests that blood group O may be a risk factor for epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H624057#H624057\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Variations in VWF levels in health and disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary hemorrhagic telangiectasia &ndash; Epistaxis is the most common presenting symptom among patients with hereditary hemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. HHT is an autosomal dominant condition, characterized by widespread mucocutaneous telangiectasias (",
"      <a class=\"graphic graphic_picture graphicRef52483 \" href=\"UTD.htm?36/32/37376\">",
"       picture 1",
"      </a>",
"      ). Ninety percent of patients with HHT present with epistaxis by age 12 years; bleeding may be mild [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/52\">",
"       52",
"      </a>",
"      ]. Epistaxis in patients with HHT progressively worsens with age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17\">",
"       17",
"      </a>",
"      ] and can be difficult to control; the friable lesions appear to bleed more with treatment than without. A high index of suspicion is necessary to make the diagnosis, which should be considered on the basis of family and clinical history in patients with multiple mucocutaneous telangiectasias [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,17\">",
"       14,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosebleeds may be more frequent, or more difficult to control in children taking certain medications, particularly antiinflammatory agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) and anticoagulants (eg, those with complex congenital heart disease or thromboembolic disease). Epistaxis related to acquired factor XIII deficiency, and von Willebrand disease have been reported in children receiving treatment with valproic acid&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In addition, anticoagulating agents (warfarins and \"superwarfarins\") are contained in a number of rodenticides, which may be unintentionally ingested by children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inflammatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloody nasal discharge may occur in various systemic inflammatory disorders, such as Wegener's granulomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/14,53,57\">",
"     14,53,57",
"    </a>",
"    ]. The most common presenting symptoms of Wegener's granulomatosis include persistent rhinorrhea,",
"    <span class=\"nowrap\">",
"     purulent/bloody",
"    </span>",
"    nasal discharge, oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal ulcers, polyarthralgias, myalgias, or pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypertension rarely results in epistaxis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/17\">",
"     17",
"    </a>",
"    ]. Secondary causes of hypertension that may result in epistaxis include renal disease and systemic corticosteroid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recurrent epistaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents, recurrent nosebleeds usually are related to chronic irritation of the nasal mucosa as may occur from dry air, chronic use of nasal medication for allergic rhinitis, recurrent upper respiratory infection, or inhalation of substances of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27912/abstract/13,18,26\">",
"     13,18,26",
"    </a>",
"    ]. However, recurrent epistaxis also may be the presenting symptom of a bleeding disorder, hereditary hemorrhagic telangiectasia, nasopharyngeal tumor, or post-traumatic pseudoaneurysm of the internal carotid artery. These disorders must be considered in the appropriate clinical setting (eg, positive family history, mucocutaneous telangiectasias, head trauma, nasopharyngeal mass head trauma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=see_link\">",
"       \"Patient information: Nosebleeds (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=see_link\">",
"       \"Patient information: Nosebleeds (epistaxis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nosebleeds are common in children. Thirty percent of children younger than five years and 56 percent of those aged 6 to 10 years have had at least one nosebleed. Nosebleeds are more common during cold weather and when ambient humidity is low. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most nosebleeds in children originate from the anterior nasal septum, in an area known as Kiesselbach's plexus, which is formed by the anastomosis of terminal vessels from the internal and external carotid arteries (",
"      <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any factors that cause congestion of the nasal vessels or drying or irritation of the nasal mucosa increase the likelihood of nosebleeds. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common causes of nosebleeds in children include trauma, dry air, nasal foreign body, and rhinitis (allergic, infectious, or related to mucosal irritation). Nasal colonization with Staphylococcus aureus is commonly found in children with recurrent epistaxis. Less common, but important, causes of nosebleeds to remember include bleeding disorders and other systemic diseases, tumors, and post-traumatic pseudoaneurysm of the internal carotid artery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local causes of nosebleeds include trauma, mucosal irritation, anatomic abnormalities, tumors, and local vascular congestion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Local causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic causes of nosebleeds include bleeding disorders, medications, neoplasms, inflammatory disorders, and hypertension. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Systemic causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent epistaxis may be the presenting symptom of a bleeding disorder, hereditary hemorrhagic telangiectasia, nasopharyngeal tumor, or pseudoaneurysm of the internal carotid artery. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Recurrent epistaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/1\">",
"      Brown NJ, Berkowitz RG. Epistaxis in healthy children requiring hospital admission. Int J Pediatr Otorhinolaryngol 2004; 68:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/2\">",
"      Petruson B. Epistaxis in childhood. Rhinology 1979; 17:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/3\">",
"      Beran M, Petruson B. Occurrence of epistaxis in habitual nose-bleeders and analysis of some etiological factors. ORL J Otorhinolaryngol Relat Spec 1986; 48:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/4\">",
"      McIntosh N, Mok JY, Margerison A. Epidemiology of oronasal hemorrhage in the first 2 years of life: implications for child protection. Pediatrics 2007; 120:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/5\">",
"      Hey E. Sudden oronasal bleeding in a young child. Acta Paediatr 2008; 97:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/6\">",
"      Paranjothy S, Fone D, Mann M, et al. The incidence and aetiology of epistaxis in infants: a population-based study. Arch Dis Child 2009; 94:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/7\">",
"      Weindling M. Nose bleeds, child protection and the difficulties faced by paediatricians. Acta Paediatr 2008; 97:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/8\">",
"      Walton LJ, Davies FC. Nasal bleeding and non-accidental injury in an infant. Arch Dis Child 2010; 95:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/9\">",
"      Bernius M, Perlin D. Pediatric ear, nose, and throat emergencies. Pediatr Clin North Am 2006; 53:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/10\">",
"      Pallin DJ, Chng YM, McKay MP, et al. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med 2005; 46:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/11\">",
"      Danielides V, Kontogiannis N, Bartzokas A, et al. The influence of meteorological factors on the frequency of epistaxis. Clin Otolaryngol Allied Sci 2002; 27:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/12\">",
"      Bray D, Monnery P, Toma AG. Airborne environmental pollutant concentration and hospital epistaxis presentation: a 5-year review. Clin Otolaryngol Allied Sci 2004; 29:655.",
"     </a>",
"    </li>",
"    <li>",
"     Edelstein DR, Khabie N. Epistaxis. In: Primary Pediatric Care, 4th, Hoekelman RA.  (Ed), Mosby, St. Louis 2001. p.1058.",
"    </li>",
"    <li>",
"     Nadel F, Henretig FM. Epistaxis. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.263.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/15\">",
"      Ruddy J, Proops DW, Pearman K, Ruddy H. Management of epistaxis in children. Int J Pediatr Otorhinolaryngol 1991; 21:139.",
"     </a>",
"    </li>",
"    <li>",
"     Tunnessen WW. Epistaxis. In: Signs and Symptoms in Pediatrics, 3rd, Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.293.",
"    </li>",
"    <li>",
"     Manning SC, Culbertson MC. Epistaxis. In: Pediatric Otolaryngology, 4th, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2002. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/18\">",
"      Guarisco JL, Graham HD 3rd. Epistaxis in children: causes, diagnosis, and treatment. Ear Nose Throat J 1989; 68:522, 528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/19\">",
"      Mulbury PE. Recurrent epistaxis. Pediatr Rev 1991; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/20\">",
"      Coleman CC Jr. Diagnosis and treatment of congenital arteriovenous fistulas of the head and neck. Am J Surg 1973; 126:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/21\">",
"      Pathak PN. Epistaxis--due to ruptured aneurysm of the internal carotid artery. J Laryngol Otol 1972; 86:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/22\">",
"      K&ouml;roglu M, Arat A, Cekirge S, et al. Giant cervical internal carotid artery pseudoaneurysm in a child: endovascular treatment. Neuroradiology 2002; 44:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/23\">",
"      Dai A, Jurges E. The problem with nose bleeds. Emerg Med J 2005; 22:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/24\">",
"      Williams PM, Traquina DN, Wallace RC, Niezgoda JJ. Coil embolization of a ruptured carotid pseudoaneurysm presenting as epistaxis--pediatric otolaryngology: principles and practice. Am J Otolaryngol 2000; 21:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/25\">",
"      Reiber ME, Burkey BB. Intracavernous carotid pseudoaneurysm after blunt trauma: case report and discussion. Head Neck 1994; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/26\">",
"      Alvi A, Joyner-Triplett N. Acute epistaxis. How to spot the source and stop the flow. Postgrad Med 1996; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/27\">",
"      Karkos PD, Karagama YG, Manivasagam A, El Badawey MR. Magnetic nasal foreign bodies: a result of fashion mania. Int J Pediatr Otorhinolaryngol 2003; 67:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/28\">",
"      Kalan A, Tariq M. Foreign bodies in the nasal cavities: a comprehensive review of the aetiology, diagnostic pointers, and therapeutic measures. Postgrad Med J 2000; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/29\">",
"      Lin VY, Daniel SJ, Papsin BC. Button batteries in the ear, nose and upper aerodigestive tract. Int J Pediatr Otorhinolaryngol 2004; 68:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/30\">",
"      Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 2003; 117:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/31\">",
"      Murray AB, Milner RA. Allergic rhinitis and recurrent epistaxis in children. Ann Allergy Asthma Immunol 1995; 74:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/32\">",
"      Whymark AD, Crampsey DP, Fraser L, et al. Childhood epistaxis and nasal colonization with Staphylococcus aureus. Otolaryngol Head Neck Surg 2008; 138:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/33\">",
"      Batra K, Chaudhary N, Motwani G, Rai AK. An unusual case of primary nasal tuberculosis with epistaxis and epilepsy. Ear Nose Throat J 2002; 81:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/34\">",
"      Faridi MM, Aggarwal A, Kumar M, Sarafrazul A. Clinical and biochemical profile of dengue haemorrhagic fever in children in Delhi. Trop Doct 2008; 38:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/35\">",
"      Ahmed S, Arif F, Yahya Y, et al. Dengue fever outbreak in Karachi 2006--a study of profile and outcome of children under 15 years of age. J Pak Med Assoc 2008; 58:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/36\">",
"      Gullane PJ, Davidson J, O'Dwyer T, Forte V. Juvenile angiofibroma: a review of the literature and a case series report. Laryngoscope 1992; 102:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/37\">",
"      Neel HB 3rd, Whicker JH, Devine KD, Weiland LH. Juvenile angiofibroma. Review of 120 cases. Am J Surg 1973; 126:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/38\">",
"      Komoroski EM. Nasopharyngeal carcinoma: early warning signs and symptoms. Pediatr Emerg Care 1994; 10:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/39\">",
"      Jafek BW, Nahum AM, Butler RM, Ward PH. Surgical treatment of juvenile nasopharyngeal angiofibroma. Laryngoscope 1973; 83:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/40\">",
"      English GM, Hemenway WG, Cundy RL. Surgical treatment of invasive angiofibroma. Arch Otolaryngol 1972; 96:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/41\">",
"      Bass IS, Haller JO, Berdon WE, et al. Nasopharyngeal carcinoma: clinical and radiographic findings in children. Radiology 1985; 156:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/42\">",
"      Norton KI, Som PM, Shugar JM. Persistent cervical adenitis and nasopharyngeal carcinoma in children. J Comput Tomogr 1987; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/43\">",
"      Roper HP, Essex-Cater A, Marsden HB, et al. Nasopharyngeal carcinoma in children. Pediatr Hematol Oncol 1986; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/44\">",
"      Phillips PP, Gustafson RO, Facer GW. The clinical behavior of inverting papilloma of the nose and paranasal sinuses: report of 112 cases and review of the literature. Laryngoscope 1990; 100:463.",
"     </a>",
"    </li>",
"    <li>",
"     Magit AE. Tumors of the nose, paranasal sinuses, and nasopharynx. In: Pediatric Otalryngology, 4th, Bluestone CD, Casselbrant ML, Stool SE, et al.  (Eds), Saunders, Philadelphia 2002. p.1053.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/46\">",
"      Eavey RD. Inverted papilloma of the nose and paranasal sinuses in childhood and adolescence. Laryngoscope 1985; 95:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/47\">",
"      Sandoval C, Dong S, Visintainer P, et al. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol 2002; 24:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/48\">",
"      Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 1998; 133:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/49\">",
"      Katsanis E, Luke KH, Hsu E, et al. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. J Pediatr 1988; 113:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/50\">",
"      Reddy VM, Daniel M, Bright E, et al. Is there an association between blood group O and epistaxis? J Laryngol Otol 2008; 122:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/51\">",
"      Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope 2002; 112:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/52\">",
"      Mei-Zahav M, Letarte M, Faughnan ME, et al. Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience. Arch Pediatr Adolesc Med 2006; 160:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/53\">",
"      Teich M, Longin E, Dempfle CE, K&ouml;nig S. Factor XIII deficiency associated with valproate treatment. Epilepsia 2004; 45:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/54\">",
"      Serdaroglu G, T&uuml;t&uuml;nc&uuml;oglu S, Kavakli K, Tekg&uuml;l H. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol 2002; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/55\">",
"      Watt BE, Proudfoot AT, Bradberry SM, Vale JA. Anticoagulant rodenticides. Toxicol Rev 2005; 24:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/56\">",
"      Watts RG, Castleberry RP, Sadowski JA. Accidental poisoning with a superwarfarin compound (brodifacoum) in a child. Pediatrics 1990; 86:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27912/abstract/57\">",
"      Orlowski JP, Clough JD, Dyment PG. Wegener's granulomatosis in the pediatric age group. Pediatrics 1978; 61:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6452 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-124.240.187.81-3C54767836-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27912=[""].join("\n");
var outline_f27_16_27912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Local causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mucosal irritation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Systemic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recurrent epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6452|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/3/33842\" title=\"diagnostic image 1\">",
"      Juvenile angiofibroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6452|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/23/374\" title=\"figure 1\">",
"      Anatomy medial nasal wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6452|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/32/37376\" title=\"picture 1\">",
"      Osler Weber Rendu",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/47/18172\" title=\"table 1\">",
"      Etiology epistaxis children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=related_link\">",
"      Management of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=related_link\">",
"      Patient information: Nosebleeds (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=related_link\">",
"      Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29785?source=related_link\">",
"      Pyogenic granuloma (Lobular capillary hemangioma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27913="Treatment of subacute and chronic cough in adults";
var content_f27_16_27913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of subacute and chronic cough in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Ronald C Silvestri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/16/27913/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/16/27913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an acute and self-limited cough often does not require therapy, prolonged cough can be a bothersome symptom that precipitates many outpatient visits to the clinician for treatment. Differing definitions for a chronic cough have been proposed that require symptoms for varying times from two weeks to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Guidelines from the American College of Chest Physicians distinguish three categories of cough based upon duration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute cough, lasting less than three weeks",
"     </li>",
"     <li>",
"      Subacute cough, lasting between three and eight weeks",
"     </li>",
"     <li>",
"      Chronic cough, lasting more than eight weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial priorities for patients with cough lasting more than three weeks (subacute or chronic cough) are to identify a precipitant or etiology, and then to eliminate the precipitant or treat the underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific therapy for the most common causes of subacute and chronic cough and nonspecific suppressive therapy for refractory cough will be reviewed here. The causes, evaluation, and complications of subacute and chronic cough are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several older studies that used a systematic approach to the evaluation and treatment of persistent cough reported that treatment aimed at the underlying disorder was successful in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. More recent studies and reviews of chronic cough, however, have found the number of patients responding fully to specific therapy to be substantially fewer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. There remains widespread agreement, nonetheless, that the initial approach to a patient with chronic cough should follow a systematic algorithmic approach to treatment aimed at the most common causes or triggers (",
"    <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial step in the algorithm identifies patients who are immunosuppressed, smoke cigarettes, or have purulent sputum. Immunosuppressed patients should have a diligent and rapid evaluation for infection. Smokers need counseling to quit smoking and often a chest radiograph to exclude bronchogenic carcinoma. Patients with significant production of purulent sputum need evaluation for pulmonary and possibly sinus infection, and treatment of identified infections, prior to proceeding with the algorithm.",
"   </p>",
"   <p>",
"    The algorithm uses a sequential approach to using specific empiric therapies for the most common causes of cough. These therapies are described in the following sections. Using an algorithm with a sequential, empiric approach to therapy is of diagnostic as well as therapeutic usefulness. Therefore, it is usually best to follow one avenue of treatment at a time rather than several branches of treatment simultaneously. If there is partial but incomplete resolution of the cough with one line of therapy, then it is reasonable to add therapy for the next most likely diagnostic possibility.",
"   </p>",
"   <p>",
"    On the other hand, some patients have more than one cause for chronic cough, particularly those seen in a referral clinic. Among such individuals, cough only resolves when all causes are successfully treated at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/5\">",
"     5",
"    </a>",
"    ]. When more than one etiology is suspected at the time of the initial evaluation and the cough is particularly disabling, empiric treatment or evaluation of likely causes can be pursued simultaneously. Once cough has resolved, treatments can be stopped sequentially, starting with the least likely to have been helpful, observing the patient for any return of cough.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Upper airway cough syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway cough syndrome (UACS; previously known as postnasal drip syndrome but revised to include all upper airway abnormalities causing cough) has a number of different etiologies, including allergic, nonallergic, and vasomotor rhinitis, acute nasopharyngitis, and sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/12\">",
"     12",
"    </a>",
"    ]. When an environmental precipitant for allergic rhinitis can be identified, exposure to this precipitant should be eliminated if at all possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practice parameters for the diagnosis and management of rhinitis have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/13\">",
"     13",
"    </a>",
"    ]. These guidelines describe high-quality evidence that intranasal glucocorticoids are the most effective therapy for symptoms of allergic rhinitis (",
"    <a class=\"graphic graphic_table graphicRef55833 \" href=\"UTD.htm?16/18/16685\">",
"     table 1",
"    </a>",
"    ). In addition, intranasal glucocorticoids are effective for several types of nonallergic rhinitis, including nonallergic rhinitis with eosinophilia (NARES) and vasomotor rhinitis. For patients with cough due to allergic rhinitis, intranasal glucocorticoids are generally effective in reducing cough within the first few days, but may take up to two weeks to achieve maximal effect. If the patient responds, therapy is continued for approximately three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional therapies for allergic rhinitis include oral and nasal antihistamines, oral decongestants, oral leukotriene receptor antagonists, and other agents. The use of these agents for allergic and nonallergic rhinitis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"     \"Chronic nonallergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients without evidence for allergic rhinitis in whom nonallergic rhinitis may be more likely, our approach is to perform a diagnostic trial with an oral first generation antihistamine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/29/39381?source=see_link\">",
"     brompheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7142?source=see_link\">",
"     clemastine",
"    </a>",
"    ) or a combined antihistamine-decongestant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36645?source=see_link\">",
"     brompheniramine-pseudoephedrine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/1,4,14\">",
"     1,4,14",
"    </a>",
"    ]. First generation antihistamines are preferred over second generation ones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ) due to the stronger anticholinergic effect, but concern over the sedating effects may limit their use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/12\">",
"     12",
"    </a>",
"    ]. Improvement in the cough should lead to further evaluation for the cause of the rhinitis (eg, allergic, nonallergic, or rhinosinusitis) and optimization of the long-term treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"     \"Chronic nonallergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with suspected nonallergic UACS who are not candidates for use of an oral first generation antihistamine (eg, due to excess somnolence), other options include intranasal administration of one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    , glucocorticoid, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/13\">",
"     13",
"    </a>",
"    ]. However, azelastine is a first generation antihistamine and may cause somnolence even with intranasal use. Intranasal ipratropium bromide significantly reduces the rhinorrhea associated with perennial nonallergic rhinitis and has few side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link&amp;anchor=H17#H17\">",
"     \"Chronic nonallergic rhinitis\", section on 'Topical antihistamine sprays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link&amp;anchor=H18#H18\">",
"     \"Chronic nonallergic rhinitis\", section on 'Prominent rhinorrhea without other symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lack of improvement in cough after one to two weeks of empiric therapy for UACS is evidence that UACS is not the cause of the cough. However, in the presence of nasal symptoms or signs, a sinus CT scan should be performed before completely excluding the possibility of UACS as a cause of cough.",
"   </p>",
"   <p>",
"    When sinusitis is documented by plain radiograph or sinus CT scan, treatment is guided by whether the patient has acute (less than 12 weeks) or chronic sinusitis. The treatment of these entities is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cough variant asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough variant asthma may be suspected based on the presence of reversible airflow obstruction or a positive test for bronchial hyperresponsiveness (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    or histamine challenge test). However, confirmation that cough is due to asthma requires a beneficial response to therapy for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/16\">",
"     16",
"    </a>",
"    ]. Therapy for cough variant asthma follows the same general principles as standard therapy for asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to therapy for moderate or severe asthma, the mainstays of therapy for cough variant asthma are regular use of inhaled glucocorticoids (GC) and as-needed use of inhaled bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/16\">",
"     16",
"    </a>",
"    ]. In a case series, for example, 10 patients with cough variant asthma were treated with inhaled GCs; all were free of disabling cough at a mean follow up of 28 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The leukotriene receptor antagonists (LTRA) have also been shown to improve cough in patients with cough variant asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/18\">",
"     18",
"    </a>",
"    ]. In a small, randomized trial of 13 patients with cough variant asthma who were refractory to treatment with inhaled bronchodilators and inhaled glucocorticoids, therapy with an LTRA resulted in decreased cough scores compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/19\">",
"     19",
"    </a>",
"    ]. LTRAs are an alternative among patients who wish to avoid or who have not responded to glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are disabled by their cough, a short (one to two week) course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    can be given, generally with excellent results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Once the patient has improved, prednisone is discontinued and maintenance therapy with inhaled GCs is continued.",
"   </p>",
"   <p>",
"    Sputum eosinophil cell count and exhaled nitric oxide measurement have been used in patients with asthma as measures of airway inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This has led some to suggest that such tests can be used by the clinician in evaluating whether patients with a suboptimal response to therapy for cough variant asthma would benefit from an escalation in their anti-inflammatory asthma treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/9\">",
"     9",
"    </a>",
"    ]. Further study of this approach is needed before widespread implementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonasthmatic eosinophilic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual treatment for nonasthmatic eosinophilic bronchitis (NAEB) is an inhaled glucocorticoid. This choice is based on observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As an example, 11 patients with NAEB received open-label treatment with inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    400 mcg per day for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/23\">",
"     23",
"    </a>",
"    ]. Severity of cough and sensitivity to capsaicin-induced cough both improved. The optimal dose and duration of therapy have not been determined.",
"   </p>",
"   <p>",
"    When an inciting agent (eg, occupational allergen) is identified, further exposure should be avoided. Rarely, oral glucocorticoids are needed for refractory symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough due to gastroesophageal reflux disease (GERD) generally responds to a regimen that includes lifestyle modifications and acid suppression medication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/7,24-26\">",
"     7,24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence in favor of lifestyle modifications to reduce or prevent GERD and thereby treat cough is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. The following interventions are based on the lifestyle modifications that are suggested for the routine management of GERD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss for patients who are overweight",
"     </li>",
"     <li>",
"      Elevation of the head of the bed three to four inches",
"     </li>",
"     <li>",
"      Cessation of smoking",
"     </li>",
"     <li>",
"      Avoidance of reflux-inducing foods (eg, fatty foods, chocolate, excess alcohol)",
"     </li>",
"     <li>",
"      Avoidance of very acidic beverages (eg, colas, red wine, orange juice)",
"     </li>",
"     <li>",
"      Avoidance of meals for two to three hours before lying down (except for medications)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lifestyle modification in the management of GERD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Lifestyle modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acid-suppression medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid suppression medications are a key component to the treatment of cough due to GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/26\">",
"     26",
"    </a>",
"    ]. However, regimens proven effective in the management of GERD may not necessarily be the optimum regimen for cough due to GERD. A meta-analysis of randomized trials of medical GERD interventions for cough showed that while such therapy indeed has some effect in adults, the effect is less universal than often suggested in consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/27\">",
"     27",
"    </a>",
"    ]. A possible explanation for failure to improve despite acid suppression is that of nonacidic reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest using an empiric trial of a proton pump inhibitor at a moderate dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    40 mg once daily in the morning). This is based on the evidence that therapy with a PPI is more effective than H",
"    <sub>",
"     2",
"    </sub>",
"    antagonist treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, as it may take up to eight weeks, and sometimes several months, to yield optimal improvement in cough, it seems reasonable to start with the more effective choice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/7,26\">",
"     7,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients whose cough does not improve after one to two months of empiric therapy, we proceed to 24 hour esophageal pH probe monitoring. Results suggestive of cough due to GERD include an abnormal amount of time with an esophageal pH less than four and cough occurring within a few minutes of reflux events. Although not widely available, dual impedance pH probe monitoring may help identify patients with nonacidic reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of prokinetic therapy such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    may be beneficial in patients with nonacidic reflux or may add to the effectiveness of acid suppression therapy in cough due to acidic reflux. However, supportive data are weak and patients placed on metoclopramide should be followed for the possible development of extrapyramidal side effects (eg, rigidity, bradykinesia, tremor, and restlessness).",
"   </p>",
"   <p>",
"    The role of surgical fundoplication to relieve extra-esophageal symptoms related to GERD is unclear. A small number of patients with cough secondary to gastroesophageal reflux disease refractory to medical measures have been treated with laparoscopic or open Nissen fundoplication. One study, which included 62 such patients, found that laparoscopic fundoplication was effective in 83 percent when symptoms were assessed six months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/29\">",
"     29",
"    </a>",
"    ]. In a meta-analysis of 25 studies, a variable portion of patients (15 to 95 percent) experienced improvement in extra-esophageal symptoms (including but not limited to cough) after surgical fundoplication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/30\">",
"     30",
"    </a>",
"    ]. The studies were all nonrandomized and used variable selection criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Following an upper respiratory tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough following an upper respiratory tract infection may be due to postnasal drip or a direct effect of the viral infection to increase bronchial reactivity or cough receptor sensitivity. Patients in whom postnasal drip (ie, upper airway cough syndrome or UACS) seems to be contributing to the prolonged cough following a viral upper respiratory tract infection should be treated the same as patients with nonallergic UACS, as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/31\">",
"     31",
"    </a>",
"    ]. First generation antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/29/39381?source=see_link\">",
"     brompheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7142?source=see_link\">",
"     clemastine",
"    </a>",
"    ), although more sedating, have stronger anticholinergic effects than second generation agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ) and therefore are superior for treating cough secondary to the common cold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/12,14,31-33\">",
"     12,14,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with postviral cough without upper airway cough syndrome, the agents described above for cough variant asthma are used. These patients often have transient bronchial hyperreactivity and a positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge test [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/16\">",
"     16",
"    </a>",
"    ]. Alternatively, in patients with postviral cough who have no evidence of airway hyperreactivity, inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide has been reported to produce improvement in the cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/34\">",
"     34",
"    </a>",
"    ]. Among 14 such patients in one report, the administration of 320 mcg of inhaled ipratropium bromide resulted in clinical improvement in 12 and complete resolution of cough in five [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection due to Bordetella pertussis (whooping cough) may be responsible for approximately 20 percent of cases of prolonged cough in adolescents and adults. It is therefore important to consider this diagnosis in the patient with an apparent postinfectious cough, especially if post-tussive vomiting is present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. Patients are treated with a macrolide antibiotic, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , if a macrolide cannot be given. However, there is limited evidence for efficacy when these medications are administered beyond the first two weeks of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme inhibitors and receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors produce a cough in 3 to 20 percent of patients, an effect that may be mediated by increased availability of kinins. The cough usually begins within one to two weeks of starting therapy, but may be delayed for as long as six months. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/37\">",
"     37",
"    </a>",
"    ], inhaled sodium cromoglycate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/38\">",
"     38",
"    </a>",
"    ], and a thromboxane antagonist (picotamide) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/39\">",
"     39",
"    </a>",
"    ] may partially alleviate this cough, the treatment of choice is withdrawal of the ACE inhibitor. The cough will typically resolve within one to four weeks after stopping the ACE inhibitor, but occasionally will last up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Cough'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin II receptor antagonists are alternatives to ACE inhibitors (acting via a related mechanism) that do not affect kinin metabolism. These agents do not appear to be associated with an increased incidence of cough, even in patients who had previously had an ACE inhibitor-induced cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Angiotensin II receptor antagonists also do not increase cough or bronchial hyperresponsiveness in symptomatic asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONSPECIFIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific therapy should be reserved for those patients who do not respond to the algorithm described above (",
"    <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"     algorithm 1",
"    </a>",
"    ). As noted, several studies have noted a substantial minority of patients who do not respond or respond inadequately to specific interventions and treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. &nbsp;Rarely, these patients may have another underlying airway or parenchymal disease as the cause of their cough. More often, however, they have what many now term &ldquo;unexplained chronic cough&rdquo;, &ldquo;chronic idiopathic cough&rdquo;, or &ldquo;cough hypersensitivity syndrome&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/43\">",
"     43",
"    </a>",
"    ]. This disorder may in part be due to an abnormally sensitive cough reflex, perhaps in the form of heightened sensory nerve receptor sensitivity due to alterations in receptor ion channels, such as transient receptor potential vanilloid 1 (TRPV1) or transient receptor potential ankyrin 1 (TRPA1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until cough receptor antagonists are developed and tested, the currently available nonspecific cough remedies described below are reasonable for the management of disabling chronic cough that has not responded to specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/3,47-49\">",
"     3,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Centrally acting antitussive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents, both opioid and non-opioid, are thought to suppress cough via an action on the central cough center. The data are limited regarding efficacy despite widespread use. We usually start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    , due to its better side effect profile. If that is ineffective, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    or long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    are tried, recognizing the risk of addiction and other narcotic-related adverse effects. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    for cough is &ldquo;off-label&rdquo;, but may be tried for cough refractory to other measures, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3936386\">",
"    <span class=\"h3\">",
"     Dextromethorphan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     Dextromethorphan",
"    </a>",
"    is probably the most common non-opioid agent used for cough. Studies that have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and dextromethorphan have shown variable results, but the number of subjects in each study was small.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cross-over study of 16 patients with chronic, stable cough,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      (20 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      (20 mg) were equally effective in reducing cough frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/50\">",
"       50",
"      </a>",
"      ]. However, because cough intensity was lowered more by dextromethorphan than by codeine, the majority of patients preferred the use of dextromethorphan.",
"     </li>",
"     <li>",
"      An observational study of eight patients demonstrated equal antitussive effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      30 mg and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      60 mg, each of which was superior to dextromethorphan 30 mg and to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3936200\">",
"    <span class=\"h3\">",
"     Codeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     Codeine",
"    </a>",
"    is the traditional opiate used for cough, although evidence regarding its efficacy for chronic cough is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. In a randomized trial of an investigational agent, 64 subjects with subacute cough were randomly assigned to receive codeine (30 mg twice daily) or placebo. Codeine reduced cough counts relative to placebo, but the effect was not statistically significant. However, the dose of codeine was low, as the usual dosing in adults is 30 to 60 mg every 4 hours. In a brief intervention study, 21 patients with cough due to chronic bronchitis were randomly assigned to codeine 60 mg twice a day or placebo for a one day study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/52\">",
"     52",
"    </a>",
"    ]. No significant difference was noted in cough counts or subjective cough scores between the study groups, although the study size was small and the dose of codeine low. In our practice, when prescribing codeine, we start at 30 mg every 4 to 6 hours as needed and increase to 60 mg, if the lower dose is insufficient. We caution patients about potential adverse effects such as somnolence and constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3936319\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    and other agents in the phenanthrene alkaloid group are effective in some but not all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/48\">",
"     48",
"    </a>",
"    ]. In a double-blind crossover trial, 27 patients who had a persistent cough of greater than three months duration and failed specific treatment were randomly assigned to receive slow-release morphine (5 mg twice daily) or placebo for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/55\">",
"     55",
"    </a>",
"    ]. Morphine improved daily cough severity scores, although the cough reflex was unaltered. Among those patients who did not respond to 5 mg twice daily, improvement was detected when the dose was increased to 10 mg twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3936335\">",
"    <span class=\"h3\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    , a gamma aminobutyric acid (GABA) analog that inhibits neurotransmitter release, is thought to ameliorate chronic neuropathic pain via a central mechanism. It is hypothesized that it may also act to reduce chronic cough via a central mechanism. In a randomized trial, 62 patients with refractory chronic cough were assigned to receive either gabapentin (in doses up to 1800 mg daily) or placebo for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/56\">",
"     56",
"    </a>",
"    ]. Cough specific quality of life measures were significantly improved in the gabapentin group. Additionally cough appeared to worsen upon cessation of the gabapentin. Side effects, chiefly nausea and fatigue, occurred in over 30 percent of those receiving gabapentin and were often managed by dose reduction.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    should be initiated at low dosage (300 mg once a day) with gradual increases until cough relief, dose limiting adverse effects, or a dose of 600 mg three times a day is achieved. Adverse effects may include diarrhea, nausea, emotional lability, somnolence, nystagmus, tremor, weakness, and peripheral edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Peripherally acting antitussive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/1/18451?source=see_link\">",
"     Benzonatate",
"    </a>",
"    is a peripherally acting antitussive agent that presumably acts by anesthetizing stretch receptors in the lungs and pleura. It has been used as a nonspecific treatment for cough since 1958. While there are few good controlled studies of its use, one report showed that a combination of 200 mg of benzonatate and 600 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    significantly suppressed capsaicin-induced cough compared to guaifenesin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/57\">",
"     57",
"    </a>",
"    ]. There are case reports of effective use of benzonatate in the palliative treatment of cough in advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/58\">",
"     58",
"    </a>",
"    ]. It may be tried as an adjunctive treatment to narcotics in such cases. Accidental ingestion of benzonatate and fatal overdoses have been reported in children &lt;10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/59\">",
"     59",
"    </a>",
"    ]. Signs and symptoms of overdose (restlessness, tremors, convulsion, coma, cardiac arrest) may occur within 15 to 20 minutes after ingestion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been evaluated as an antitussive agent for patients with cough due to idiopathic pulmonary fibrosis (IPF). The mechanism by which thalidomide might suppress cough in IPF is not known, but it is speculated to be due to its anti-inflammatory or antifibrotic properties or to its inhibition of pulmonary sensory nerve fibers. In a randomized cross over trial, participants were randomly assigned to receive either thalidomide (in doses up to 100 mg daily) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/60\">",
"     60",
"    </a>",
"    ]. Cough was significantly decreased in the thalidomide group compared to placebo, although patients in the thalidomide group had more adverse events, chiefly constipation, dizziness, and viral upper respiratory infections. Additional study of thalidomide is needed before widespread implementation for chronic cough, because of its serious adverse effect profile, including teratogenicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H4990318#H4990318\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that chronic cough is associated with airway inflammation even in nonasthmatic patients, has prompted use of inhaled glucocorticoids (GCs) for nonspecific management of chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/61\">",
"     61",
"    </a>",
"    ]. However, studies of inhaled glucocorticoids for the treatment of cough in the absence of asthma have yielded conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, for example, there was a suggestion that more patients with chronic cough responded to inhaled GCs than to placebo, although overall mean daily cough scores were not significantly different in the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study showed no benefit of inhaled GCs in patients with chronic nonasthmatic cough [",
"      <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences in observed efficacy may be due to the presence of patients with eosinophilic bronchitis in some studies. These patients would not have physiologic evidence of asthma, but would likely respond to inhaled GCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ipratropium bromide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticholinergic agent, inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, has been proposed to have at least two potential mechanisms by which it may alleviate cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blocking the efferent limb of the cough reflex",
"     </li>",
"     <li>",
"      Decreasing stimulation of cough receptors by alteration of mucociliary factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    has been noted in a small group of patients with persistent cough following upper respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/16/27913/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       \"Patient information: Cough in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"       \"Patient information: Chronic cough in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first priority for management of a patient with persistent cough is establishing an etiology, so that therapy can be directed at the underlying cause (",
"      <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"       algorithm 1",
"      </a>",
"      ). The best approach is to use a systematic combination of empiric therapy and objective testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"       \"Evaluation of subacute and chronic cough in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Specific treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with upper airway cough syndrome (UACS) who have a personal or family history suggestive of atopy, we recommend treatment with an intranasal glucocorticoid, rather than an oral antihistamine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Combination therapy with an intranasal glucocorticoid and an oral antihistamine is an acceptable alternative, particularly in a patient with severe symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Upper airway cough syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with suspected upper airway cough syndrome, but no features to suggest atopy, we suggest empiric treatment with a first generation oral antihistamine, rather than a second generation antihistamine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A first generation intranasal antihistamine is an acceptable alternative. Addition of an oral decongestant medication may provide additional benefit. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Upper airway cough syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with subacute or chronic cough due to suspected cough variant asthma, we recommend regular use of an inhaled glucocorticoid and as-needed use of an inhaled bronchodilator, rather than use of an inhaled bronchodilator alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Combination therapy with a leukotriene receptor antagonist and an as-needed, short-acting inhaled bronchodilator is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cough variant asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients suspected of having a cough due to gastroesophageal reflux should be advised regarding lifestyle modifications. In addition, we recommend using an empiric trial of acid suppression medication therapy, rather than direct testing for gastroesophageal reflux (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Proton pump inhibitors appear to be more effective than H",
"      <sub>",
"       2",
"      </sub>",
"      antagonists in this setting. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Gastroesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cough following an upper respiratory infection and clinical features suggestive of UACS, we suggest treatment with an oral first generation antihistamine, rather than a second generation antihistamine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The addition of on oral or intranasal decongestant may be beneficial to some patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Following an upper respiratory tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cough following an upper respiratory infection, but few or no features of UACS, we treat bronchial hyperreactivity, as described above for cough variant asthma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Following an upper respiratory tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop a chronic cough while taking angiotensin converting enzyme inhibitors (ACEI), we recommend stopping the ACEI rather than trying to suppress the cough with other agents (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The cough will usually resolve within a couple of weeks, although it will occasionally last up to four months. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Specific treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nonspecific therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are patients for whom the etiology of the cough cannot be identified, no specific therapy exists, or specific therapy has failed. For such patients, we suggest treatment with the non-opioid agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      , rather than using an opioid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/1/18451?source=see_link\">",
"       Benzonatate",
"      </a>",
"      can be added if the cough persists despite dextromethorphan. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonspecific treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a cough due to an unrelenting cause or a persistent cough despite both specific therapy and nonspecific therapy with non-opioid agents, we suggest a trial of an opioid antitussive (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      are commonly used opioid antitussives. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonspecific treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is an alternative, &ldquo;off-label&rdquo; possibility for patients whose cough is refractory to the above measures. (See",
"      <a class=\"local\" href=\"#H3936335\">",
"       'Gabapentin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/1\">",
"      Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/2\">",
"      Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/3\">",
"      Irwin RS, Curley FJ. The treatment of cough. A comprehensive review. Chest 1991; 99:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/4\">",
"      Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000; 343:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/5\">",
"      Palombini BC, Villanova CA, Ara&uacute;jo E, et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest 1999; 116:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/6\">",
"      Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis 1981; 123:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/7\">",
"      Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/8\">",
"      Pratter MR, Bartter T, Akers S, DuBois J. An algorithmic approach to chronic cough. Ann Intern Med 1993; 119:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/9\">",
"      Birring SS. Controversies in the evaluation and management of chronic cough. Am J Respir Crit Care Med 2011; 183:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/10\">",
"      Woodcock A, Young EC, Smith JA. New insights in cough. Br Med Bull 2010; 96:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/11\">",
"      Haque RA, Usmani OS, Barnes PJ. Chronic idiopathic cough: a discrete clinical entity? Chest 2005; 127:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/12\">",
"      Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. Chest 2006; 129:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/13\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/14\">",
"      Curley FJ, Irwin RS, Pratter MR, et al. Cough and the common cold. Am Rev Respir Dis 1988; 138:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/15\">",
"      Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/16\">",
"      Dicpinigaitis PV. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:75S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/17\">",
"      Cheriyan S, Greenberger PA, Patterson R. Outcome of cough variant asthma treated with inhaled steroids. Ann Allergy 1994; 73:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/18\">",
"      Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol 2004; 93:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/19\">",
"      Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma 2002; 39:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/20\">",
"      Hunter CJ, Brightling CE, Woltmann G, et al. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/21\">",
"      Chatkin JM, Ansarin K, Silkoff PE, et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care Med 1999; 159:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/22\">",
"      Brightling CE. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:116S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/23\">",
"      Brightling CE, Ward R, Wardlaw AJ, Pavord ID. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J 2000; 15:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/24\">",
"      Irwin RS, French CL, Curley FJ, et al. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 1993; 104:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/25\">",
"      Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest 2003; 123:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/26\">",
"      Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:80S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/27\">",
"      Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; :CD004823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/28\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/29\">",
"      Allen CJ, Anvari M. Gastro-oesophageal reflux related cough and its response to laparoscopic fundoplication. Thorax 1998; 53:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/30\">",
"      Iqbal M, Batch AJ, Spychal RT, Cooper BT. Outcome of surgical fundoplication for extraesophageal (atypical) manifestations of gastroesophageal reflux disease in adults: a systematic review. J Laparoendosc Adv Surg Tech A 2008; 18:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/31\">",
"      Pratter MR. Cough and the common cold: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:72S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/32\">",
"      Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treatment of the common cold. Ann Allergy 1991; 67:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/33\">",
"      Berkowitz RB, Connell JT, Dietz AJ, et al. The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Ann Allergy 1989; 63:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/34\">",
"      Braman SS. Postinfectious cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:138S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/35\">",
"      Holmes PW, Barter CE, Pierce RJ. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 1992; 86:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/36\">",
"      Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/37\">",
"      Cazzola M, Matera MG, Liccardi G, et al. Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough. Respiration 1993; 60:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/38\">",
"      Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. Lancet 1995; 345:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/39\">",
"      Malini PL, Strocchi E, Zanardi M, et al. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997; 350:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/40\">",
"      Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:169S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/41\">",
"      Lacourci&egrave;re Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/42\">",
"      Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/43\">",
"      Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung 2010; 188 Suppl 1:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/44\">",
"      Mitchell JE, Campbell AP, New NE, et al. Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough. Exp Lung Res 2005; 31:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/45\">",
"      Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/46\">",
"      Grace MS, Belvisi MG. TRPA1 receptors in cough. Pulm Pharmacol Ther 2011; 24:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/47\">",
"      Belvisi MG, Geppetti P. Cough. 7: Current and future drugs for the treatment of chronic cough. Thorax 2004; 59:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/48\">",
"      Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and protussives. A practical review. Drugs 1993; 46:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/49\">",
"      Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:238S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/50\">",
"      Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983; 11:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/51\">",
"      Aylward M, Maddock J, Davies DE, et al. Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Respir Dis 1984; 65:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/52\">",
"      Smith J, Owen E, Earis J, Woodcock A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/53\">",
"      Woodcock A, McLeod RL, Sadeh J, Smith JA. The efficacy of a NOP1 agonist (SCH486757) in subacute cough. Lung 2010; 188 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/54\">",
"      Chung KF. Currently available cough suppressants for chronic cough. Lung 2008; 186 Suppl 1:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/55\">",
"      Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med 2007; 175:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/56\">",
"      Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/57\">",
"      Dicpinigaitis PV, Gayle YE, Solomon G, Gilbert RD. Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough. Respir Med 2009; 103:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/58\">",
"      Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med 1998; 12:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/59\">",
"      McLawhorn MW, Goulding MR, Gill RK, Michele TM. Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration. Pharmacotherapy 2013; 33:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/60\">",
"      Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/61\">",
"      Boulet LP, Milot J, Boutet M, et al. Airway inflammation in nonasthmatic subjects with chronic cough. Am J Respir Crit Care Med 1994; 149:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/16/27913/abstract/62\">",
"      Evald T, Munch EP, Kok-Jensen A. Chronic non-asthmatic cough is not affected by inhaled beclomethasone dipropionate. A controlled double blind clinical trial. Allergy 1989; 44:510.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1428 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27913=[""].join("\n");
var outline_f27_16_27913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Upper airway cough syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cough variant asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonasthmatic eosinophilic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acid-suppression medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Following an upper respiratory tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONSPECIFIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Centrally acting antitussive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3936386\">",
"      - Dextromethorphan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3936200\">",
"      - Codeine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3936319\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3936335\">",
"      - Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Peripherally acting antitussive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ipratropium bromide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nonspecific therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1428|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/14/10465\" title=\"algorithm 1\">",
"      Algorithm for cough evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1428|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/18/16685\" title=\"table 1\">",
"      Glucocorticoid nasal sprays",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27914="Lopinavir and ritonavir: Pediatric drug information";
var content_f27_16_27914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lopinavir and ritonavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"    see \"Lopinavir and ritonavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30933?source=see_link\">",
"    see \"Lopinavir and ritonavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Use in combination with other antiretroviral agents:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage is based on patient body weight or surface area and is presented here based on lopinavir component.",
"     <b>",
"      Once-daily dosing has not been studied in pediatric patients, and therefore, is",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      recommended.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;14 days or PMA &lt;42 weeks: Do not use in patients PNA &lt;14 days",
"     <b>",
"      or",
"     </b>",
"     PMA &lt;42 weeks due to potential toxicity from excipients; no data about appropriate dose or safety exists [DHHS (pediatric), 2011]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;14 days and PMA &ge;42 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       without",
"      </span>",
"     </b>",
"     <b>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     : Lopinavir 16 mg/kg/dose or 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Neonates who receive the 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily may have lower trough concentrations compared to adults; evaluate neonates and adjust dose for incremental growth at frequent intervals [DHHS (pediatric), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       with",
"      </span>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     : Dosage information does not exist; lopinavir/ritonavir is not recommended in neonates who are receiving these agents.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"      see \"Lopinavir and ritonavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Use in combination with other antiretroviral agents:",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric dosage is based on patient body weight or surface area and is presented here based on lopinavir component.",
"     <b>",
"      Do not exceed recommended adult dose.",
"     </b>",
"     Use of tablets in patients &lt;15 kg or &lt;0.6 m",
"     <sup>",
"      2",
"     </sup>",
"     is",
"     <b>",
"      not",
"     </b>",
"     recommended (use oral solution).",
"     <b>",
"      Once-daily dosing has not been studied in pediatric patients, and therefore, is",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      recommended.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infants 1-6 months:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       without",
"      </span>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     : Lopinavir 16 mg/kg/dose or 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Infants who receive 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily may have lower trough concentrations compared to adults; evaluate infants and adjust dose for incremental growth at frequent intervals [DHHS (pediatric), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       with",
"      </span>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     : Dosage information does not exist; lopinavir/ritonavir is not recommended in patients &le;6 months of age who are receiving these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infants &gt;6 months, Children, and Adolescents:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       without",
"      </span>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA-based dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Lopinavir 230 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 400 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Alternative dosing for patients who are able to swallow tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA &ge;0.6 to &lt; 0.9 m",
"     <sup>",
"      2",
"     </sup>",
"     :  Lopinavir 200 mg/ritonavir 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA &ge;0.9 to &lt; 1.4 m",
"     <sup>",
"      2",
"     </sup>",
"     : Lopinavir 300 mg/ritonavir 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA &ge;1.4 m",
"     <sup>",
"      2",
"     </sup>",
"     : Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      Info",
"     </i>",
"     guidelines [DHHS (pediatric), 2011]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;6-12 months: Lopinavir 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Infants who receive 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily may have lower trough concentrations compared to adults; evaluate infants and adjust dose for incremental growth at frequent intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;12 months to 18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Antiretroviral naive: Lopinavir 230 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 400 mg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     For patients already receiving lopinavir and ritonavir, an immediate dosage reduction at 12 months of age is",
"     <b>",
"      not",
"     </b>",
"     recommended; patients are allowed to &ldquo;grow into&rdquo; the 230 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose dosage as they gain weight over time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Antiretroviral experienced: Lopinavir 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 400 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-based dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Weight-directed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;15 kg: Lopinavir 12 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;15-40 kg: Lopinavir 10 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;40 kg: Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative dosing for patients who are able to swallow tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;15-25 kg: Lopinavir 200 mg/ritonavir 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;25-35 kg: Lopinavir 300 mg/ritonavir 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;35 kg: Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      Info",
"     </i>",
"     guidelines [DHHS (pediatric), 2011]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;6-12 months: Lopinavir 16 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;12 months to 18 years: Refer to weight-directed dosing above",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       with",
"      </span>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine",
"     </b>",
"     (or treatment-experienced patients not receiving these agents in whom decreased susceptibility to lopinavir is suspected):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA-based dosing: Lopinavir 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum lopinavir dose: Oral solution: 533 mg/dose; Tablet: 500 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative dosing for patients who are able to swallow tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     BSA &ge;0.6 to &lt;0.8 m",
"     <sup>",
"      2",
"     </sup>",
"     :  Lopinavir 200 mg/ritonavir 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     BSA &ge;0.8 to &lt; 1.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : Lopinavir 300 mg/ritonavir 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     BSA &ge;1.2 to &lt; 1.7 m",
"     <sup>",
"      2",
"     </sup>",
"     : Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     BSA &ge;1.7 m",
"     <sup>",
"      2",
"     </sup>",
"     : Lopinavir 500 mg/ritonavir 125 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Therapy-experienced patients in whom decreased susceptibility to lopinavir is suspected or confirmed may receive lopinavir 600 mg/ritonavir 150 mg twice daily [DHHS (pediatric), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-directed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:2em;text-align:justify;\">",
"     &lt;15 kg: Lopinavir 13 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;15-45 kg: Lopinavir 11 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;45 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: Lopinavir 533 mg/ritonavir 133 mg (6.5 mL) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Tablets: Lopinavir 500 mg/ritonavir 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative dosing for patients who are able to swallow tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;15-20 kg: Lopinavir 200 mg/ritonavir 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;20-30 kg: Lopinavir 300 mg/ritonavir 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;30-45 kg: Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;45 kg: Lopinavir 500 mg/ritonavir 125 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Therapy-experienced patients in whom decreased susceptibility to lopinavir is suspected or confirmed may receive lopinavir 600 mg/ritonavir 150 mg twice daily [DHHS (pediatric), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       without",
"      </span>",
"     </b>",
"     <b>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Therapy-naive or therapy-experienced: Lopinavir 400 mg/ritonavir 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     This regimen is preferred (with zidovudine and lamivudine or zidovudine and emtricitabine) in pregnant, therapy-naive patients (DHHS, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily dosing:",
"     <b>",
"      Antiretroviral-naive patients or experienced patients with &lt;3 lopinavir resistance-associated amino acid substitutions in protease enzyme",
"     </b>",
"     : Lopinavir 800 mg/ritonavir 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Once-daily dosing is",
"     <b>",
"      not",
"     </b>",
"     recommended for pediatric patients &lt;18 years of age, antiretroviral-experienced patients with &ge;3 lopinavir-resistance-associated substitutions (L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V), or for patients receiving efavirenz, fosamprenavir, nelfinavir, nevirapine, carbamazepine, phenobarbital, or phenytoin; once-daily dosing has not been evaluated with concurrent use of indinavir or saquinavir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving concomitant antiretroviral therapy",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       with",
"      </span>",
"     </b>",
"     <b>",
"      efavirenz, fosamprenavir, nelfinavir, or nevirapine: Note:",
"     </b>",
"     Once-daily dosing is",
"     <b>",
"      not",
"     </b>",
"     recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral solution: Lopinavir 533 mg/ritonavir 133 mg (6.5 mL) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablets: Lopinavir 500 mg/ritonavir 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Has not been studied in patients with renal impairment; however, a decrease in clearance is not expected. Avoid once daily dosing in patients on hemodialysis (DHHS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Lopinavir AUC may be increased ~30% in patients with mild-to-moderate hepatic impairment; use with caution. No data available in patients with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaletra&reg;: Lopinavir 80 mg and ritonavir 20 mg per 1 mL (160 mL) [contains ethanol 42.4%, menthol, propylene glycol; cotton candy flavor]]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaletra&reg;:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Lopinavir 100 mg and ritonavir 25 mg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Lopinavir 200 mg and ritonavir 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143461.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143461.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Administer with food to enhance bioavailability and decrease kinetic variability; use a calibrated oral dosing syringe to measure and administer the oral solution;",
"     <b>",
"      Note:",
"     </b>",
"     Dose must be accurately measured and administered to pediatric patients as oral solution is very concentrated and a fatal accidental overdose has been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: May be administered without regard to meals; swallow tablets whole, do not crush, break, or chew",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until dispensed; refrigerated products are stable until labeled expiration date; stability at room temperature: 2 months; avoid exposure to excessive heat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Store at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Dispense in original container or USP equivalent tight container. Do not expose to high humidity outside original container or USP equivalent tight container for &gt;2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in ages &ge;14 days and adults); (",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of three antiretroviral agents are strongly recommended).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential for dispensing errors between Kaletra&reg; and Keppra&reg; (levETIRAcetam)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Children&rsquo;s doses are based on weight and calculated by milligrams of lopinavir. Care should be taken to accurately calculate the dose. The oral solution contains lopinavir 80 mg and ritonavir 20 mg per one mL. Children &lt;12 years of age (and &le;40 kg) who are not taking certain concomitant antiretroviral medications will receive &lt;5 mL of solution per dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data presented for short- and long-term combination antiretroviral therapy in both protease inhibitor experienced and na&iuml;ve patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, atrioventricular block, cerebral infarction, chest pain, deep vein thrombosis, edema, facial edema, hypertension, MI, orthostatic hypotension, palpitation, peripheral edema, vasculitis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, apathy, ataxia, chills, confusion, depression, dizziness, emotional lability, encephalopathy, extrapyramidal symptoms, facial paralysis, fatigue, fever, headache, insomnia, malaise, migraine, nervousness, neuropathy, peripheral neuropathy, seizure, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, benign neoplasm, cellulitis, dry skin, eczema, exfoliative dermatitis, folliculitis, furunculosis, hyperhidrosis, maculopapular rash, pruritus, rash, seborrhea, skin discoloration, skin ulcer, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, Cushing's syndrome, dehydration, diabetes mellitus, glucose intolerance, gynecomastia, hypercholesterolemia, hyperglycemia, hyperuricemia, hypogonadism (males), hypothyroidism, inorganic phosphorus decreased, lactic acidosis, libido decreased, sodium decreased or increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension/pain, abnormal taste/taste perversion, amylase increased, anorexia, appetite increased/decreased, constipation, diarrhea, dyspepsia, dysphagia, enteritis, enterocolitis, eructation, esophagitis, fecal incontinence, flatulence, gastritis, gastroenteritis, GERD, hemorrhagic colitis, hemorrhoids, lipase increased, mouth ulceration, nausea, pancreatitis, periodontitis, sialadenitis, splenomegaly, stomatitis, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Abnormal ejaculation, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, lymphadenopathy, neutropenia, platelets decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, cholangitis, cholecystitis, fatty deposits, GGT increased, hepatic dysfunction, hepatitis, hepatomegaly, jaundice, liver tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, dyskinesia, hypertonia, joint disorder, myalgia, myasthenia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Abnormal vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Hyperacusis, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine clearance decreased, nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Asthma, bronchitis, cough, dyspnea, lung edema, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, avitaminosis, bacterial infection, bone necrosis, cyst, flu-like syndrome, hypertrophy, immune reconstitution syndrome, obesity, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: AV block (second and third degree), body fat redistribution, bradyarrhythmia, erythema multiforme, neoplasm, propylene glycol toxicity (preterm neonates [includes cardiomyopathy, lactic acidosis, acute renal failure, respiratory complications]), PR prolongation, QT prolongation, Stevens-Johnson syndrome, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis) to lopinavir, ritonavir, or any component; concurrent therapy with medications that largely rely on cytochrome P450 isoenzymes CYP3A for clearance and that have an association between increased plasma concentrations and serious or life-threatening effects [eg, alfuzosin, cisapride, dihydroergotamine, ergonovine, ergotamine, lovastatin, methylergonovine, midazolam (oral), pimozide, sildenafil (when used for pulmonary arterial hypertension), simvastatin, triazolam]; concurrent therapy with strong CYP3A4 inducers that significantly decrease lopinavir serum concentrations which may lead to treatment failure or development of resistance [eg, rifampin or the herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     )]",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Once-daily dosing: Adult patients with &ge;3 lopinavir-resistance-associated substitutions (L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V); those receiving amprenavir, efavirenz, nevirapine, or nelfinavir, carbamazepine, phenobarbital, phenytoin, or in children &lt;18 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment (lopinavir and ritonavir are primarily metabolized by the liver); hepatitis or markedly elevated transaminases prior to therapy may increase risk for developing or worsening elevations in liver enzymes or for hepatic decompensation; hepatic dysfunction (including fatalities) have been reported; in general, these occurred in patients with advanced HIV disease who were taking multiple concomitant medications and who had underlying chronic hepatitis or cirrhosis; a causal relationship with lopinavir/ritonavir has not been established; monitor liver enzymes prior to therapy and periodically during treatment; consider more frequent monitoring of liver enzymes in patients with concurrent chronic hepatitis or cirrhosis, especially during the first few months of lopinavir/ritonavir therapy. May alter cardiac conduction and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     and/or PR interval; second and third degree AV block and torsade de pointes have been observed; use with caution in patients with underlying structural heart disease, pre-existing conduction system abnormalities, ischemic heart disease, or cardiomyopathies. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     - or PR-interval prolonging drugs or in patients with hypokalemia or congenital long-QT syndrome. Spontaneous bleeding episodes have been reported in patients with hemophilia type A and B receiving protease inhibitors. Large increases in total cholesterol (incidence: 3% to 19%; children: 3%) and triglycerides (incidence: 4% to 36%) have been reported; patients should be monitored prior to therapy and periodically during treatment. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). May cause diarrhea (5% to 28%; children: 12%); in one adult study, incidence of diarrhea was higher in patients receiving once-daily dosing compared to twice-daily dosing. Children may have a higher incidence of vomiting (21% vs &le;6%). May cause taste perversion in children (incidence: 22%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lopinavir and ritonavir are potent CYP3A isoenzyme inhibitors that interact with numerous drugs. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated and other medications may require concentration monitoring or dosage adjustment if coadministered with lopinavir and ritonavir. Concomitant use with certain medications may require dosage adjustment of lopinavir and ritonavir.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Potentially fatal pancreatitis may occur; markedly elevated serum triglycerides is a risk factor for developing pancreatitis; advanced HIV disease or a history of pancreatitis may also place patients at increased risk; discontinue lopinavir and ritonavir therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. New onset diabetes mellitus, exacerbations of diabetes, and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors. Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including lopinavir/ritonavir; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serious cardiac, renal, CNS, or respiratory problems have been reported in preterm neonates receiving lopinavir/ritonavir oral solution. The oral solution contains 42.4% ethanol (v/v) and 15.3% propylene glycol (w/v). Ethanol competitively inhibits propylene glycol metabolism, which may lead to propylene glycol toxicity due to impaired elimination in neonates. Preterm neonates are at an increased risk of adverse events from propylene glycol toxicity, including cardiotoxicity (complete AV block, bradycardia, cardiomyopathy), lactic acidosis, CNS depression, respiratory complications, acute renal failure, and death. Do not use oral solution in neonates if the patient is either PNA &lt;14 days old or PMA &lt;42 weeks. Due to concentration of ethanol in oral solution, an overdose in a child may cause potentially lethal alcohol toxicity. Treatment for overdose should be supportive and include general poisoning management; activated charcoal may help remove unabsorbed medication; dialysis unlikely to be of benefit; however, dialysis can remove alcohol and propylene glycol. In pediatric patients 14 days to 6 months of age, the total amounts of ethanol and propylene glycol delivered from all medications should be considered to avoid toxicity. Neonates and young infants should be closely monitored for increases in serum osmolality, serum creatinine, and other signs of propylene glycol toxicity (eg, CNS depression, seizures, cardiac arrhythmias, hemolysis); in neonates particularly, symptoms should be distinguished from sepsis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A fatal accidental overdose occurred in a 2.1 kg, 44-day old infant (born at 30 weeks gestational age) with HIV who received a single dose of 6.5 mL of lopinavir/ritonavir oral solution. The infant died of cardiogenic shock 9 days later. Healthcare providers are reminded that lopinavir/ritonavir oral solution is highly concentrated. To minimize the risk for medication errors, healthcare providers should pay special attention to accurate calculation of the dose, transcription of the medication order, dispensing information, dosing instructions, and proper measurement of the dose. New pediatric tablets containing lopinavir 100 mg and ritonavir 25 mg (ie,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the amount in regular tablets) are now available; caution should be taken so that dosing and dispensing errors do not occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F189791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Ritonavir may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Ritonavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking lopinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting lopinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Lopinavir may decrease the serum concentration of BuPROPion. Concentrations of the active metabolite, hydroxybupropion, may also be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Ritonavir may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Lopinavir. Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Ritonavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Lopinavir may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Ritonavir may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Ritonavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Lopinavir may decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution, which must be taken with food, and is principally the result of a food-didanosine interaction.  Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of lopinavir/ritonavir oral solution (which must be taken with food).  Didanosine and lopinavir/ritonavir tablets can be administered together.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Ritonavir. This is specific for the lopinavir/ritonavir (Kaletra) oral solution due to its alcohol content (42%). Management: Concomitant use of Kaletra (lopinavir/ritonavir) oral solution and disulfiram should be avoided. Kaletra contains 42% alcohol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronabinol: Ritonavir may increase the serum concentration of Dronabinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estazolam: Ritonavir may increase the serum concentration of Estazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Ritonavir may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Ritonavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Ritonavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Ritonavir may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Lopinavir. Specifically, amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir. Management: Lopinavir/ritonavir should not be used as a once daily regimen when used together with fosamprenavir.  The use of ritonavir-boosted fosamprenavir with lopinavir/ritonavir may negate this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin. Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Lopinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Ritonavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Ritonavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Ritonavir may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: Ritonavir may increase the serum concentration of Linagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Lopinavir may increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nelfinavir.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Lopinavir. Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Lopinavir may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.  Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Ritonavir may increase the serum concentration of PrednisoLONE (Systemic).  Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Ritonavir may increase the serum concentration of PredniSONE.  Management: Consider prednisone dose reductions in patients receiving ritonavir, and monitor for increased prednisone levels/adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Ritonavir may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Ritonavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Lopinavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Lopinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Lopinavir may increase the serum concentration of Rilpivirine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ritonavir may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Lopinavir may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Lopinavir may enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Lopinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamcinolone (Systemic): Ritonavir may enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Lopinavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Ritonavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Lopinavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Ritonavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Ritonavir may decrease the serum concentration of Voriconazole.  Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Lopinavir may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Lopinavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ritonavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compared to fasting, a moderate fat meal increased lopinavir AUC by 80% (oral solution), but by only 26.9% for the tablets; a high fat meal increased lopinavir AUC by 130% (oral solution), but by only 18.9% for the tablets",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not seen in animal reproduction studies, except at doses which were also maternally toxic. Lopinavir/ritonavir crosses the placenta; however, based on information collected by the Antiretroviral Pregnancy Registry, an increased risk of teratogenic effects has not been observed in humans. The DHHS Perinatal HIV Guidelines consider lopinavir/ritonavir to be the preferred protease inhibitor for use in antiretroviral-naive pregnant women. Due to a decrease in bioavailability, a dose increase is suggested during the second and third trimesters of pregnancy, especially in PI-experienced women. Monitor virologic response (and lopinavir serum concentrations if available) if the standard dose is used. Once-daily dosing is not recommended during pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of pancreatitis; serum electrolytes, glucose, triglycerides, cholesterol, liver enzymes, bilirubin, amylase, CBC with differential, platelets, CD4 cell count, HIV RNA plasma level. Due  to potential toxicity from excipients in the oral solution, in pediatric patients 14 days to 6 months of age, the total amounts of ethanol and propylene glycol delivered from all medications should be monitored to avoid toxicity. Neonates and young infants should be closely monitored for increases in serum osmolality, serum creatinine, and other signs of propylene glycol toxicity (eg, CNS depression, seizures, cardiac arrhythmias, hemolysis); in neonates particularly, symptoms should be distinguished from sepsis.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product is a fixed-dose combination of lopinavir and ritonavir; antiretroviral effects are due to lopinavir, a protease inhibitor; lopinavir acts on an enzyme (protease) late in the HIV replication process after the virus has entered into the cell's nucleus. Lopinavir binds to the protease activity site and inhibits the activity of the enzyme, thus preventing cleavage of viral polyprotein precursors (gag-pol protein precursors) into individual functional proteins found in infectious HIV. This results in the formation of immature, noninfectious viral particles. Ritonavir inhibits the metabolism of lopinavir via the cytochrome P450 CYP3A isoenzyme pathway and significantly increases plasma concentrations of lopinavir.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information below refers to Lopinavir; see Ritonavir for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to 99%; binds to both alpha",
"     <sub>",
"      1",
"     </sub>",
"     - acid glycoprotein and albumin; higher affinity for alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein; decreased protein binding in patients with mild to moderate hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily oxidative, via cytochrome P450 CYP3A isoenzyme; 13 oxidative metabolites identified; may induce its own metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute bioavailability not established; AUC for oral solution was 22% lower than capsule when given under fasting conditions; concentrations were similar under nonfasting conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Mean: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 2.2% of dose eliminated unchanged in urine; 83% of dose eliminated in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: (Apparent oral): 6-7 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Unlikely to remove significant amounts of drug (due to high protein binding)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30933?source=see_link\">",
"      see \"Lopinavir and ritonavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of lopinavir and ritonavir. Lopinavir and ritonavir is not a cure for HIV. Notify physician if symptoms of pancreatitis occur (nausea, vomiting, abdominal pain). Report the use of other medications, nonprescription medications and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort. Lopinavir and ritonavir may interfere with certain oral contraceptives and contraceptive patch; alternate contraceptive measures may be needed (consult with physician). Special care should be taken to accurately measure and administer oral solution to pediatric patients to decrease the risk of accidental overdose or underdose. Contact a healthcare professional immediately if a neonate or young infant receiving lopinavir/ritonavir exhibits signs or symptoms of propylene glycol or ethanol toxicity (eg, appears too sleepy or breathing has changed during therapy).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Take lopinavir and ritonavir everyday as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Lopinavir and ritonavir may cause changes in the ECG or rhythm of the heart; notify physician if you experience dizziness, lightheadedness, abnormal heart rhythm, or loss of consciousness.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Preliminary studies have reported response rates (defined as viral loads &lt;400 copies/mL) of 91%, 81%, and 33% for patients with 0-5, 6-7, and 8-10 protease mutations at baseline, respectively (Hurst, 2000).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" March 27, 2012.  Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hurst M and Faulds D, &ldquo;Lopinavir,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 60(6):1371-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27914/abstract-text/11152017 /pubmed\" id=\"11152017 \" target=\"_blank\">",
"        11152017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mangum EM and Graham KK, &ldquo;Lopinavir-Ritonavir: A New Protease Inhibitor,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(11):1352-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27914/abstract-text/11714208/pubmed\" id=\"11714208\" target=\"_blank\">",
"        11714208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JL and Kraus DM, \"New Antiretroviral Therapies for Pediatric HIV Infection,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2005, 10:215-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piscitelli SC, Burstein AH, Chaitt D, et al, &ldquo;Indinavir Concentrations and St John's Wort,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9203):547-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/16/27914/abstract-text/10683007/pubmed\" id=\"10683007\" target=\"_blank\">",
"        10683007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12562 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27914=[""].join("\n");
var outline_f27_16_27914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189777\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053711\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443857\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053704\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189754\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189740\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885304\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053707\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189804\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189801\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053703\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053702\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189791\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189748\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053721\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189750\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189763\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053710\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053701\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053717\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053709\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053719\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=related_link\">",
"      Lopinavir and ritonavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30933?source=related_link\">",
"      Lopinavir and ritonavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_16_27915="Diff dx sudden severe headache";
var content_f27_16_27915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of sudden onset severe headache",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expansion or thrombosis of unruptured intracranial aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracerebral hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute ischemic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subdural and epidural hematomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal carotid and vertebral artery dissection (with face or neck pain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary apoplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid cyst of the third ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute expansion of mass lesion in the posterior fossa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous intracranial hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coital headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute narrow angle glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exertional headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute sinusitis (with barotrauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign thunderclap headaches",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27915=[""].join("\n");
var outline_f27_16_27915=null;
var title_f27_16_27916="Reducing pediatric lead exposure";
var content_f27_16_27916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56262%7EPEDS%2F63418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56262%7EPEDS%2F63418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Provider steps in reducing continued lead exposure in children with elevated blood lead levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Report to appropriate health authorities (eg, city, county, or state health department).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Take emergency measures to reduce lead exposure. Relocate the child and family to lead-free housing if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Initiate intensive blood lead screening and/or chelation as determined by the degree of the child's blood lead elevation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Educate the family about sources of lead exposure so that they can be eliminated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Follow-up on long-term abatement procedures to reduce lead exposure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Steps to take to minimize lead absorption in your family",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Make sure that your children wash their hands and face before eating and sleeping.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Prevent your children from eating things other than food (eg, dirt, paint).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Make sure that all surfaces (floors, countertops, tabletops, etc) have been thoroughly cleaned with a detergent. This is especially important for toddlers since they crawl and lay on the floor and frequently put their hands in their mouths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. If your home was built prior to 1977, it is extremely important to remove any flaking or peeling paint in the house, since older homes frequently were painted with lead-based paint. Hire or consult a professional certified in lead paint abatement. Painting over lead-based paint, or applying wallpaper, are only temporary ways to control exposure, and are not acceptable means of control. Protective equipment and respirators must be worn in the removal of lead-based paint from walls and woodwork.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Make sure that your children receive the recommended daily allowance of multivitamins with iron. They should have well-balanced diets that include a combination of fruits, vegetables, grains, protein, and dairy products.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Do not use herbal or folk medicine (these may contain lead).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. If you are not sure if your pottery has a lead glaze, use it only for decoration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Store food in glass, plastic, or stainless steel containers, not in open cans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Use water from the cold tap for cooking and drinking. Let it run for several minutes before collecting for use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Be careful to keep materials for hobbies, such as those used for making ceramics or stained glass, away from children and areas where they spend time.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27916=[""].join("\n");
var outline_f27_16_27916=null;
var title_f27_16_27917="Contents: Impulse control disorders";
var content_f27_16_27917=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Impulse control disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Impulse control disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/44/15049\">",
"           Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26760\">",
"           Intermittent explosive disorder in adults: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22760\">",
"           Pathologic gambling",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-0DBB6D9739-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_16_27917=[""].join("\n");
var outline_f27_16_27917=null;
var title_f27_16_27918="B cell surface markers I";
var content_f27_16_27918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78500%7ERHEUM%2F57546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78500%7ERHEUM%2F57546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surface markers during B cell development-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Antigen-independent phase",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Antigen-dependent phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pre-pro B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pro-B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pre B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Immature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Activated B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blast B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Memory B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plasma B cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MHC Class II",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD10",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD19",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD21",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD23",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD25, IL-2R alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD32, Fc gamma RII",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD34",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD35, CR1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD80/86, B7-1/2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IL: interleukin; R: receptor; alpha: alpha chain.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102 (no table number).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surface markers during B cell development-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Antigen-independent phase",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Antigen-dependent phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pre-pro B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pro-B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pre B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Immature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Activated B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blast B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Memory B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plasma B cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD121, IL-1R",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD122, IL-2R beta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD123, IL-3R alpha",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD124, IL-4R alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD125, IL-5R alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD126, IL-6R alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD127, IL-7R alpha",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IL: interleukin; R: receptor; alpha: alpha chain.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_16_27918=[""].join("\n");
var outline_f27_16_27918=null;
var title_f27_16_27919="Contents: Primary care pulmonary disease";
var content_f27_16_27919=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care pulmonary disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care pulmonary disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute respiratory distress syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/16/10505\">",
"           Acute respiratory distress syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29945\">",
"           Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4871\">",
"           Acute respiratory distress syndrome: Prognosis and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8618\">",
"           Beta agonists in asthma: Acute administration and prophylactic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/19/16698\">",
"           Beta agonists in asthma: Controversy regarding chronic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19482\">",
"           Diagnosis of asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12789\">",
"           Enhancing patient adherence to asthma therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19653\">",
"           Epidemiology of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39816\">",
"           Gastroesophageal reflux and asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29226\">",
"           Management of asthma during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34824\">",
"           Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14489\">",
"           Occupational asthma: Management, prognosis, and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5607\">",
"           Office spirometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19159\">",
"           Physiology and clinical course of asthma in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18856\">",
"           The use of inhaler devices in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/56/5002\">",
"           Treatment of acute exacerbations of asthma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18154\">",
"           Treatment of intermittent and mild persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26745\">",
"           Treatment of moderate persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22487\">",
"           Use of pulmonary function testing in the diagnosis of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         COPD",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/14/30954\">",
"           Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35351\">",
"           Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23641\">",
"           Management of acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39338\">",
"           Management of stable chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18856\">",
"           The use of inhaler devices in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/21/44373\">",
"           Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/20/22856\">",
"           Approach to the adult with interstitial lung disease: Clinical evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/10/16553\">",
"           Approach to the patient with dyspnea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/8/1162\">",
"           Evaluation of preoperative pulmonary risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32391\">",
"           Evaluation of pulmonary disability",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5418\">",
"           Evaluation of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28938\">",
"           Evaluation of the adult with dyspnea in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/35/25144\">",
"           Exercise physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4952\">",
"           Overview of pulmonary function testing in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/32/22022\">",
"           Overview of snoring in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/51/13113\">",
"           Strategies to reduce postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2008\">",
"           Treatment of adults with snoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27913\">",
"           Treatment of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10341\">",
"           Adherence to tuberculosis treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3162\">",
"           Mycoplasma pneumoniae infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17591\">",
"           Sputum cultures for the evaluation of bacterial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9432\">",
"           Treatment of latent tuberculosis infection in HIV-negative adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Smoking issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18968\">",
"           Benefits and risks of smoking cessation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1482\">",
"           Cardiovascular risk of smoking and benefits of smoking cessation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/3/23609\">",
"           Overview of smoking cessation management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/34997\">",
"           Patterns of tobacco use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/13/17626\">",
"           Pharmacotherapy for smoking cessation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22505\">",
"           Secondhand smoke exposure: Effects in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12904\">",
"           Smoking cessation counseling strategies in primary care",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thromboembolic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6042\">",
"           Diagnosis of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/12/33994\">",
"           Diagnosis of suspected deep vein thrombosis of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43786\">",
"           Overview of the causes of venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41802\">",
"           Prevention of venous thromboembolic disease in surgical patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42503\">",
"           Treatment of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-7CEF5D6727-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_16_27919=[""].join("\n");
var outline_f27_16_27919=null;
